<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Chem</journal-id><journal-id journal-id-type="iso-abbrev">Front Chem</journal-id><journal-id journal-id-type="publisher-id">Front. Chem.</journal-id><journal-title-group><journal-title>Frontiers in Chemistry</journal-title></journal-title-group><issn pub-type="epub">2296-2646</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8120161</article-id><article-id pub-id-type="publisher-id">608438</article-id><article-id pub-id-type="doi">10.3389/fchem.2021.608438</article-id><article-categories><subj-group subj-group-type="heading"><subject>Chemistry</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Structure Activity Relationship of <italic>N</italic>-Substituted Phenyldihydropyrazolones Against <italic>Trypanosoma cruzi</italic> Amastigotes</article-title><alt-title alt-title-type="left-running-head">Sijm et al.</alt-title><alt-title alt-title-type="right-running-head">Phenyldihydropyrazolones Inhibitors Against <italic>Trypanosoma</italic><italic>cruzi</italic></alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sijm</surname><given-names>Maarten</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1092161/overview"/></contrib><contrib contrib-type="author"><name><surname>Maes</surname><given-names>Louis</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/274828/overview"/></contrib><contrib contrib-type="author"><name><surname>de Esch</surname><given-names>Iwan J. P.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Caljon</surname><given-names>Guy</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/325070/overview"/></contrib><contrib contrib-type="author"><name><surname>Sterk</surname><given-names>Geert Jan</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1119735/overview"/></contrib><contrib contrib-type="author"><name><surname>Leurs</surname><given-names>Rob</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="c001">*</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/460473/overview"/></contrib></contrib-group><aff id="aff1">
<label><sup>1</sup></label>Division of Medicinal Chemistry, Faculty of Sciences, The Amsterdam Institute of Molecular and Life Sciences (AIMMS), Vrije Universiteit Amsterdam, <addr-line>Amsterdam</addr-line>, <country>Netherlands</country>
</aff><aff id="aff2">
<label><sup>2</sup></label>Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, <addr-line>Antwerp</addr-line>, <country>Belgium</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/60162/overview">Gildardo Rivera</ext-link>, Instituto Polit&#x000e9;cnico Nacional (IPN), Mexico</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/668669/overview">Gabriella Gabriella</ext-link>, University of Florence, Italy</p><p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/53664/overview">Guillermo R. Labadie</ext-link>, National University of Rosario, Argentina</p><p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/669794/overview">Andrei I. Khlebnikov</ext-link>, Tomsk Polytechnic University, Russia</p></fn><corresp id="c001">*Correspondence: Rob Leurs, <email>r.leurs@vu.nl</email></corresp><fn fn-type="other"><p>This article was submitted to Medicinal and Pharmaceutical Chemistry, a section of the journal Frontiers in Chemistry</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>4</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>9</volume><elocation-id>608438</elocation-id><history><date date-type="received"><day>20</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>4</month><year>2021</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2021 Sijm, Maes, de Esch, Caljon, Sterk and Leurs.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Sijm, Maes, de Esch, Caljon, Sterk and Leurs</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Current drugs for Chagas disease have long treatment regimens with occurrence of adverse drug effects leading to poor treatment compliance. Novel and efficacious medications are therefore highly needed. We previously reported on the discovery of NPD-0227 (2-isopropyl-5-(4-methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one) as a potent <italic>in vitro</italic> inhibitor of <italic>Trypanosoma cruzi</italic> (pIC<sub>50</sub> = 6.4) with 100-fold selectivity over human MRC-5 cells. The present work describes a SAR study on the exploration of substituents on the phenylpyrazolone nitrogen. Modifications were either done directly onto this pyrazolone nitrogen or alternatively by introducing a piperidine linker. Attention was pointed toward the selection of substituents with a cLogP preferably below NPD-0227s cLogP of 3.5. Generally the more apolar compounds showed better activities then molecules with cLogPs &#x0003c;2.0. Several new compounds were identified with potencies that are in the same range as NPD-0227 (pIC<sub>50</sub> = 6.4) and promising selectivities. While the potency could not be improved, valuable SAR was obtained. Furthermore the introduction of a piperidine linker offers new opportunities for derivatization as valuable novel starting points for future <italic>T. cruzi</italic> drug discovery.</p></abstract><kwd-group><kwd>structure activity relationship</kwd><kwd>chagas disease</kwd><kwd>phenotypic optmization</kwd><kwd>trypanosama cruzi</kwd><kwd>phenylpyrazolones</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">FP7 Health<named-content content-type="fundref-id">10.13039/100011272</named-content></funding-source></award-group></funding-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The protozoan parasite <italic>Trypanosoma cruzi</italic> is the causative agent of Chagas disease. It is estimated that over six million people are infected worldwide, the majority in Latin-America where the parasite is endemic. (<xref rid="B13" ref-type="bibr">Lidani et al., 2019</xref>; <xref rid="B27" ref-type="bibr">WHO, 2021</xref>). <italic>T. cruzi</italic> is spread by several insect vectors, most of which belong to the triatomine family (<xref rid="B12" ref-type="bibr">Kollien and Schaub, 2000</xref>; <xref rid="B14" ref-type="bibr">Martinez et al., 2019</xref>). Other ways of transmission are <italic>via</italic> blood transfusions, laboratory accidents or parental transmission from mother to infant (<xref rid="B22" ref-type="bibr">Schmunis, 1999</xref>; <xref rid="B26" ref-type="bibr">Torrico et al., 2004</xref>; <xref rid="B21" ref-type="bibr">Rassi et al., 2010</xref>). The life cycle of <italic>T. cruzi</italic> consists of several developmental stages in the mammalian host and insect vector (<xref rid="B21" ref-type="bibr">Rassi et al., 2010</xref>). While the vector appears unaffected by the parasite, infected humans can develop life-threatening symptoms and pathologies. The acute stage of the disease starts shortly after the parasite enters the body but a strong immune response will cause a large reduction of the initial peak of parasitemia, however, without full elimination of the parasite leading to persistent infection of certain tissues (<xref rid="B10" ref-type="bibr">Dias, 1984</xref>). The acute symptoms are non-specific, such as fever, mild splenomegaly and edema, making diagnosis diffucult (<xref rid="B19" ref-type="bibr">Prata, 2001</xref>). After 2&#x000a0;months, the disease enters the chronic phase in which the parasite becomes dormant and no symptoms are observed. This dormant phase can last for over 10&#x000a0;years up to lifelong (<xref rid="B19" ref-type="bibr">Prata, 2001</xref>). Estimates of further evolution of chronic infection toward clinical symptoms, such as cardiopathy or megaesophagus and megacolon, ranges between 10&#x02013;60% of infected people and varies widely in different regions (<xref rid="B9" ref-type="bibr">Coura and Vi&#x000f1;as, 2010</xref>; <xref rid="B8" ref-type="bibr">Coura and Borges-Pereira, 2011</xref>). Patients can become life-long asymptomatic carriers thus representing a parasite reservoir.</p><p>Vector control, early diagnosis and effective chemotherapy are essential to combat Chagas disease. Two drugs are currently marketed: the nitro-imidazole benznidazole (<bold>1,</bold>
<xref ref-type="fig" rid="F1">Figure 1</xref>) and the nitro-furan nifurtimox (<bold>2</bold>) (<xref rid="B21" ref-type="bibr">Rassi et al., 2010</xref>). Both drugs contain a nitro-aromatic functionality which is commonly associated with toxic side effects. Furthermore, the treatment regimens of both vary between 60&#x02013;90&#x000a0;days and are known to cause various side effects which cause patients to discontinue their treatment (<xref rid="B7" ref-type="bibr">Castro et al., 2006</xref>; <xref rid="B18" ref-type="bibr">Pinazo et al., 2013</xref>). Benznidazole (<bold>1</bold>) is currently used as first-line treatment as it has a better overall safety profile (<xref rid="B1" ref-type="bibr">Alpern et al., 2017</xref>). While the efficacy of both drugs is well established in the acute phase, much debate is ongoing on about their efficacy in the chronic phase (<xref rid="B23" ref-type="bibr">Sgambatti de Andrade et al., 1996</xref>; <xref rid="B28" ref-type="bibr">Zhang and Tarleton, 1999</xref>; <xref rid="B5" ref-type="bibr">Bern, 2011</xref>). The recent BENEFIT trial investigated the efficacy of Benznidazole (<bold>1</bold>) on chronic Chagas&#x02019; heart disease. While reduced parasitemia was observed by PCR, this did not result in significant reduction of clinical deterioration of cardiac function after 5&#x000a0;years (<xref rid="B17" ref-type="bibr">Morillo et al., 2015</xref>). Afterward several concerns were raised in literature with regard to the PCR analysis and benznidazole dosage, precluding firm conclusions on the efficacy potential in the chronic phase of infection (<xref rid="B11" ref-type="bibr">Hamers et al., 2016</xref>).</p><fig id="F1" position="float"><label>FIGURE 1</label><caption><p>Current drugs used against Chagas disease: the nitro-imidazole benznidazole (<bold>1</bold>) and nitro-furan nifurtimox (<bold>2</bold>), and the recently discovered <italic>T. cruzi</italic> inhibitor NPD-0227 (<bold>3</bold>).</p></caption><graphic xlink:href="fchem-09-608438-g001"/></fig><p>The overall need for new and improved chemotherapies for Chagas disease is high, both for current and future patients. New medication is also needed as contingency measure for upcoming resistance against the available current drugs (<xref rid="B9" ref-type="bibr">Coura and Vi&#x000f1;as, 2010</xref>; <xref rid="B16" ref-type="bibr">Mejia et al., 2012</xref>). Unfortunately, the pipeline toward new drugs is largely empty. Most research on <italic>T. cruzi</italic> is performed in academia though the last few years several public-private collaborations have been initiated. In this paper, we describe part of the research of the EU-funded, public-private consortium PDE4NPD, that focuses on 3&#x02032;5&#x02032;-cyclic nucleotide phosphodiesterases (PDEs) as targets against several neglected tropical diseases. The present work further elaborates the SAR of the previously reported <italic>T. cruzi</italic> inhibitor NPD-0227 (<bold>3</bold>, <xref ref-type="fig" rid="F1">Figure 1</xref>) and investigates the role of different substituents on the pyrazolone nitrogen (<xref rid="B24" ref-type="bibr">Sijm et al., 2019</xref>). Besides the SAR aiming at improving potency, compounds were also specifically designed to improve physicochemical properties, such as cLogP and solubility. As <italic>T. cruzi</italic> ultimately proceeds <italic>via</italic> a dormant intracellular form, a possible drug needs to pass several cell membranes before reaching the parasite. During this process the drug is transferred multiple times between hydrophobic and hydrophilic phases, as such an optimal cLogP is thought to be between 0 and 2 and the drug having no charges (<xref rid="B2" ref-type="bibr">Basore et al., 2015</xref>; <xref rid="B4" ref-type="bibr">Bennion et al., 2017</xref>).</p><sec id="s1-1"><title>Chemistry</title><p>Phenylpyrazolone analogues with a substituent directly on the pyrazolone nitrogen atom were synthesized using two different routes. The first route started with a Suzuki reaction to obtain dihydropyrazolone <bold>5</bold> (Route A, <xref ref-type="fig" rid="sch01">Scheme 1</xref>) which was then functionalized using sodium hydride and various acyl chlorides and sulfonylchlorides to obtain compounds <bold>6</bold>&#x02013;<bold>10</bold> (<xref rid="T1" ref-type="table">Table 1</xref>). The second route (Route B) started with alkylation of the dihydropyrazolone <bold>4</bold>, either using potassium carbonate to yield intermediates <bold>11</bold>&#x02013;<bold>12</bold>, or using sodium hydride to generate intermediates <bold>13</bold>&#x02013;<bold>18</bold>. These intermediates were then converted to the 3-pyridinyl derivatives <italic>via</italic> a Suzuki cross coupling, yielding final compounds <bold>20</bold>&#x02013;<bold>26</bold> (<xref ref-type="fig" rid="sch01">Scheme 1</xref>, <xref rid="T1" ref-type="table">Table 1</xref>).</p><fig id="sch01" position="float"><label>SCHEME 1</label><caption><p>Reagents and conditions: a: 3-pyridinyl-B (OH)<sub>2</sub>, Pd (dppf)Cl<sub>2</sub>. DCM, Na<sub>2</sub>CO<sub>3</sub>, DME:H<sub>2</sub>O, 120 &#x000b0;C, 1&#x000a0;h, 12&#x02013;78%, b: R-COCl (<bold>6</bold>, <bold>7</bold>, <bold>8</bold>) or R-SO<sub>2</sub>Cl (<bold>9</bold>, <bold>10</bold>), NaH, DMF, rt, 18&#x000a0;h, 39&#x02013;77%, c: epoxide (<bold>11</bold>&#x02013;<bold>12</bold>), K<sub>2</sub>CO<sub>3</sub>, DMF, 100 &#x000b0;C, 16&#x000a0;h, 59&#x02013;63%, d: R-Br (<bold>13</bold>&#x02013;<bold>17</bold>) or R-Cl (<bold>18</bold>), NaH, DMF, rt, 18&#x000a0;h, 36&#x02013;94%.</p></caption><graphic xlink:href="fchem-09-608438-g002"/></fig><table-wrap id="T1" position="float"><label>TABLE 1</label><caption><p>
<italic>In vitro</italic> activity against intracellular amastigotes of <italic>T.cruzi</italic> (Tulahuen strain)<xref ref-type="table-fn" rid="Tfn1">
<sup>a</sup>
</xref> and MRC-5 cells<xref ref-type="table-fn" rid="Tfn1">
<sup>a</sup>
</xref> of phenyldihydropyrazolones with modifications directly on the pyrazolone nitrogen.</p></caption><table frame="hsides" rules="groups"><tbody valign="top"><tr><td colspan="12" align="center" rowspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx1.jpg"/>
</td></tr></tbody></table><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Cpd</th><th align="center" rowspan="1" colspan="1">R</th><th align="center" rowspan="1" colspan="1">
<italic>T.cruzi</italic> (pIC<sub>50</sub>)</th><th align="center" rowspan="1" colspan="1">MRC-5 (pIC<sub>50</sub>)</th><th align="center" rowspan="1" colspan="1">SI<xref ref-type="table-fn" rid="Tfn2">
<sup>b</sup>
</xref>
</th><th align="center" rowspan="1" colspan="1">cLogP</th><th align="center" rowspan="1" colspan="1">Cpd</th><th align="center" rowspan="1" colspan="1">R</th><th align="center" rowspan="1" colspan="1">
<italic>T.cruzi</italic> (pIC<sub>50</sub>)</th><th align="center" rowspan="1" colspan="1">MRC-5 (pIC<sub>50</sub>)</th><th align="center" rowspan="1" colspan="1">SI<xref ref-type="table-fn" rid="Tfn2">
<sup>b</sup>
</xref>
</th><th align="center" rowspan="1" colspan="1">cLogP</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx2.jpg"/>
</td><td align="center" rowspan="1" colspan="1">6.4</td><td align="center" rowspan="1" colspan="1">4.4</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">3.5</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx3.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;10</td><td align="center" rowspan="1" colspan="1">3.4</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx4.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" rowspan="1" colspan="1">3.2</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx5.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.6</td><td align="center" rowspan="1" colspan="1">4.9</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">4.8</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx6.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" rowspan="1" colspan="1">3.9</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx7.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.5</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">3.8</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx8.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" rowspan="1" colspan="1">4.1</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx9.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" rowspan="1" colspan="1">2.3</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx10.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx11.jpg"/>
</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">N.D.</td><td align="center" rowspan="1" colspan="1">2.5</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx12.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.0</td><td align="center" rowspan="1" colspan="1">4.4</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">3.6</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx13.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;8</td><td align="center" rowspan="1" colspan="1">1.5</td></tr><tr><td align="left" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx14.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx15.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;10</td><td align="center" rowspan="1" colspan="1">2.5</td></tr><tr><td align="left" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx16.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;8</td><td align="center" rowspan="1" colspan="1">3.4</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx17.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.2</td><td align="center" rowspan="1" colspan="1">4.2</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1.3</td></tr><tr><td align="left" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx18.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx19.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2.4</td></tr></tbody></table><table-wrap-foot><fn id="Tfn1"><label>a</label><p>All reported values are measured as duplicates and had a standard deviation less then &#x000b1;0.2.</p></fn><fn id="Tfn2"><label>b</label><p>Selectivity index was calculated as IC<sub>50</sub> MRC-5 cells divided by IC<sub>50</sub>
<italic>T. cruzi</italic>.</p></fn></table-wrap-foot></table-wrap><p>Introduction of methylene-oxadiazoles on the pyrazolone head group started with the previously synthesized ester analogues <bold>13</bold> and <bold>14</bold> (<xref ref-type="fig" rid="sch02">Scheme 2</xref>). Subsequent hydrazination yielded the corresponding hydrazides (<bold>27</bold> and <bold>28</bold>) which were ring-closed with either triethylorthoformate or cyanuric bromide to deliver the unsubstituted oxadiazoles (<bold>29</bold> and <bold>31</bold>) and the amine substituted oxadiazoles (<bold>30</bold> and <bold>32</bold>) respectively. These oxadiazoles were then converted to the corresponding 3-pyridinyl analogues <italic>via</italic> a Suzuki cross-coupling to yield compounds <bold>33</bold>&#x02013;<bold>36</bold>.</p><fig id="sch02" position="float"><label>SCHEME 2</label><caption><p>Reagents and conditions: a: N<sub>2</sub>H<sub>4</sub>, EtOH, rt, 18&#x000a0;h, 90&#x02013;94%, b: (EtO)<sub>3</sub>CH, reflux,18&#x000a0;h, 34&#x02013;78% (<bold>29</bold>&#x02013;<bold>30</bold>), c: BrCN, NaHCO<sub>3</sub>, MeOH, H<sub>2</sub>O, o. n., 22&#x02013;46% (<bold>31</bold>&#x02013;<bold>32</bold>), d: 3-pyridinyl-B (OH)<sub>2</sub>, Pd (dppf) Cl<sub>2</sub>. DCM, Na<sub>2</sub>CO<sub>3</sub>, DME:H<sub>2</sub>O, 120 &#x000b0;C, 1&#x000a0;h 36&#x02013;74%.</p></caption><graphic xlink:href="fchem-09-608438-g003"/></fig><p>The synthesis of the piperidine substituted dihydropyrazolones started with keto-ester <bold>37</bold> (<xref ref-type="fig" rid="sch03">Scheme 3</xref>) which was prepared according to previously reported methodology (<xref rid="B24" ref-type="bibr">Sijm et al., 2019</xref>). This keto-ester was condensed with 4-hydrazinylpiperidine to yield piperidine substituted dihydropyrazolone <bold>38</bold>. The piperidine nitrogen atom was protected using boc-anhydride to give intermediate (<bold>39</bold>) which could be used in a Suzuki cross-coupling to install the 3-pyridine moiety. Subsequent deprotection of <bold>40</bold> with 4&#x000a0;M HCl in dioxane yielded the free amine building block (<bold>41</bold>) which was used to install the desired electrophiles (<bold>42</bold>&#x02013;<bold>83</bold>, <xref rid="T2" ref-type="table">Tables 2</xref>,<xref rid="T3" ref-type="table">3</xref>) <italic>via</italic> various methodologies.</p><fig id="sch03" position="float"><label>SCHEME 3</label><caption><p>Reagents and conditions: a: 4-hydrazinylpiperidine.2HCl, MeOH, H<sub>2</sub>O, reflux, 3&#x000a0;days, 80%, b: Boc<sub>2</sub>O, TEA, DCM, rt, 4&#x000a0;h, 89%, c: 3-pyridinyl-B (OH)<sub>2</sub>, Pd (dppf) Cl<sub>2</sub>. DCM, Na<sub>2</sub>CO<sub>3</sub>, DME:H<sub>2</sub>O, 120 &#x000b0;C, 1&#x000a0;h, 86%, d: 4&#x000a0;M HCl in dioxane, rt, 18&#x000a0;h, 84%, e: R-COCl (<bold>42</bold>, <bold>43</bold>), R-SO<sub>2</sub>Cl (<bold>48</bold>), NaH, DMF, rt, 2&#x000a0;h, 38&#x02013;42%, f: EDCI, HOBt, RCOOH (<bold>44</bold>, <bold>46</bold>), DIPEA, DCM, 18&#x02013;30&#x000a0;h, 23&#x02013;31%, g: oxazole-5-carboxylic acid (<bold>45</bold>), T3P, DIPEA, EtOAc, 50 &#x000b0;C, 70&#x000a0;h, 7%, h: R-COCl (<bold>47</bold>) or R-SO<sub>2</sub>Cl (<bold>49</bold>&#x02013;<bold>54</bold>) or OCN-R (<bold>55</bold>, <bold>57</bold>&#x02013;<bold>59</bold>, <bold>61</bold>) or Cl (CO)NR<sub>1</sub>R<sub>2</sub> (<bold>56</bold>, <bold>60</bold>), TEA, DCM, rt, 2&#x02013;42&#x000a0;h, 13&#x02013;79%, i: epoxide (<bold>62</bold>&#x02013;<bold>66</bold>), DMAP, i-PrOH, 50&#x02013;100 &#x000b0;C, 2&#x02013;120&#x000a0;h, 4&#x02013;30%, j: formic acid (<bold>67</bold>), formaldehyde, 18&#x000a0;h, rt, 15%, k: R-CO-R (<bold>68&#x02013;69</bold>, <bold>71</bold>, <bold>74</bold>), NaBH (OAc)<sub>3</sub>, AcOH, DCE, 70 &#x000b0;C, 18&#x02013;72&#x000a0;h, 10&#x02013;53%, l: R-Br (<bold>70</bold>), K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 48&#x000a0;h, 10%, m: methylacrylate (<bold>72</bold>), DBN, ACN, 90h, rt, 45%, n: ClCH<sub>2</sub>CO-R (<bold>73</bold>), K<sub>2</sub>CO<sub>3</sub>, ACN, 24&#x000a0;h, rt, 39%, m: HCO-R (<bold>74</bold>&#x02013;<bold>78</bold>), NaBH (OAc)<sub>3</sub>, AcOH, DCE, 22&#x02013;72&#x000a0;h, 5&#x02013;48%, q: Ar-Br (<bold>79</bold>&#x02013;<bold>80</bold>), Pd<sub>2</sub> (dba)<sub>3</sub>, BINAP, NaOtBu, 80 &#x000b0;C, 7&#x000a0;days, 11&#x02013;19%, r: Cl-Ar (<bold>81</bold>), Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90 &#x000b0;C, 4&#x000a0;h, 24%, s: F-Ar (<bold>82</bold>), DMSO, K<sub>2</sub>CO<sub>3</sub>, 110 &#x000b0;C, 6&#x000a0;days, 16% t: i: (<bold>83</bold>) NaHCO<sub>3</sub>, 4-NO<sub>2</sub>Ph-chloroformate, dioxane, rt, 22&#x000a0;h, ii: K<sub>2</sub>CO<sub>3</sub>, morpholine, DMF, rt, 4&#x000a0;days.</p></caption><graphic xlink:href="fchem-09-608438-g004"/></fig><table-wrap id="T2" position="float"><label>TABLE 2</label><caption><p>
<italic>In vitro</italic> activity against intracellular amastigotes of <italic>T.cruzi</italic> (Tulahuen strain)<xref ref-type="table-fn" rid="Tfn3">
<sup>a</sup>
</xref> and MRC-5 cells<xref ref-type="table-fn" rid="Tfn3">
<sup>a</sup>
</xref> of phenyldihydropyrazolones with a piperidine linker.</p></caption><table frame="hsides" rules="groups"><tbody valign="top"><tr><td colspan="12" align="center" rowspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx20.jpg"/>
</td></tr></tbody></table><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Cpd</th><th align="center" rowspan="1" colspan="1">R</th><th align="center" rowspan="1" colspan="1">
<italic>T.cruzi</italic> (pIC<sub>50</sub>)</th><th align="center" rowspan="1" colspan="1">MRC-5 (pIC<sub>50</sub>)</th><th align="center" rowspan="1" colspan="1">SI<xref ref-type="table-fn" rid="Tfn4">
<sup>b</sup>
</xref>
</th><th align="center" rowspan="1" colspan="1">cLogP</th><th align="center" rowspan="1" colspan="1">Cpd</th><th align="center" rowspan="1" colspan="1">R</th><th align="center" rowspan="1" colspan="1">
<italic>T.cruzi</italic> (pIC<sub>50</sub>)</th><th align="center" rowspan="1" colspan="1">MRC-5 (pIC<sub>50</sub>)</th><th align="center" rowspan="1" colspan="1">SI<xref ref-type="table-fn" rid="Tfn4">
<sup>b</sup>
</xref>
</th><th align="center" rowspan="1" colspan="1">cLogP</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx21.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.9</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;50</td><td align="center" rowspan="1" colspan="1">3.6</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx22.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.2</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.1</td></tr><tr><td align="left" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx23.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" rowspan="1" colspan="1">2.7</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx24.jpg"/>
</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">N.D.</td><td align="center" rowspan="1" colspan="1">4.4</td></tr><tr><td align="left" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx25.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.2</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.6</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx26.jpg"/>
</td><td align="center" rowspan="1" colspan="1">6.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" rowspan="1" colspan="1">3.8</td></tr><tr><td align="left" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx27.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" rowspan="1" colspan="1">2.1</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx28.jpg"/>
</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">N.D.</td><td align="center" rowspan="1" colspan="1">1.6</td></tr><tr><td align="left" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx29.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.6</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;3</td><td align="center" rowspan="1" colspan="1">1.6</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx30.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" rowspan="1" colspan="1">2.0</td></tr><tr><td align="left" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx31.jpg"/>
</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">N.D.</td><td align="center" rowspan="1" colspan="1">0.9</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx32.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.9</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;5</td><td align="center" rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx33.jpg"/>
</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">N.D.</td><td align="center" rowspan="1" colspan="1">3.8</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx34.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.5</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">3.2</td></tr><tr><td align="left" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx35.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" rowspan="1" colspan="1">1.4</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx36.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.9</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">4.0</td></tr><tr><td align="left" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx37.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.0</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;6</td><td align="center" rowspan="1" colspan="1">2.2</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx38.jpg"/>
</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">N.D.</td><td align="center" rowspan="1" colspan="1">3.6</td></tr><tr><td align="left" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx39.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;8</td><td align="center" rowspan="1" colspan="1">2.5</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx40.jpg"/>
</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">N.D.</td><td align="center" rowspan="1" colspan="1">1.8</td></tr><tr><td align="left" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx41.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;8</td><td align="center" rowspan="1" colspan="1">1.4</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx42.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.9</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;5</td><td align="center" rowspan="1" colspan="1">1.8</td></tr></tbody></table><table-wrap-foot><fn id="Tfn3"><label>a</label><p>All reported values are measured as duplicates and had a standard deviation less then &#x000b1;0.2.</p></fn><fn id="Tfn4"><label>b</label><p>Selectivity index was calculated as IC<sub>50</sub> MRC-5 cells divided by IC<sub>50</sub>
<italic>T. cruzi</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>TABLE 3</label><caption><p>
<italic>In vitro</italic> activity against intracellular amastigotes of <italic>T.cruzi</italic> (Tulahuen strain)<xref ref-type="table-fn" rid="Tfn5">
<sup>a</sup>
</xref> and MRC-5 cells<xref ref-type="table-fn" rid="Tfn5">
<sup>a</sup>
</xref> toxicity by phenyldihydropyrazolones with a piperidine linker.</p></caption><table frame="hsides" rules="groups"><tbody valign="top"><tr><td colspan="12" align="center" rowspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx43.jpg"/>
</td></tr></tbody></table><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Cpd</th><th align="center" rowspan="1" colspan="1">R</th><th align="center" rowspan="1" colspan="1">
<italic>T.cruzi</italic> (pIC<sub>50</sub>)</th><th align="center" rowspan="1" colspan="1">MRC-5 (pIC<sub>50</sub>)</th><th align="center" rowspan="1" colspan="1">SI<xref ref-type="table-fn" rid="Tfn6">
<sup>b</sup>
</xref>
</th><th align="center" rowspan="1" colspan="1">cLogP</th><th align="center" rowspan="1" colspan="1">Cpd</th><th align="center" rowspan="1" colspan="1">R</th><th align="center" rowspan="1" colspan="1">
<italic>T.cruzi</italic> (pIC<sub>50</sub>)</th><th align="center" rowspan="1" colspan="1">MRC-5 (pIC<sub>50</sub>)</th><th align="center" rowspan="1" colspan="1">SI<xref ref-type="table-fn" rid="Tfn6">
<sup>b</sup>
</xref>
</th><th align="center" rowspan="1" colspan="1">cLogP</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">H</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">N.D</td><td align="center" rowspan="1" colspan="1">2.3</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx44.jpg"/>
</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">N.D.</td><td align="center" rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx45.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3.0</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx46.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" rowspan="1" colspan="1">1.6</td></tr><tr><td align="left" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx47.jpg"/>
</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">N.D</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">74</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx48.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.0</td><td align="center" rowspan="1" colspan="1">4.6</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3.5</td></tr><tr><td align="left" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx49.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">4.6</td><td align="center" rowspan="1" colspan="1">&#x0003c;1</td><td align="center" rowspan="1" colspan="1">3.4</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx50.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.6</td><td align="center" rowspan="1" colspan="1">4.6</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">4.4</td></tr><tr><td align="left" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx51.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.6</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;25</td><td align="center" rowspan="1" colspan="1">3.8</td><td align="center" rowspan="1" colspan="1">76</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx52.jpg"/>
</td><td align="center" rowspan="1" colspan="1">6.1</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">4.6</td></tr><tr><td align="left" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx53.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.7</td><td align="center" rowspan="1" colspan="1">5.2</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3.9</td><td align="center" rowspan="1" colspan="1">77</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx54.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.3</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">3.2</td></tr><tr><td align="left" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx55.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.4</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" rowspan="1" colspan="1">2.7</td><td align="center" rowspan="1" colspan="1">78</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx56.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.7</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">3.2</td></tr><tr><td align="left" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx57.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" rowspan="1" colspan="1">3.5</td><td align="center" rowspan="1" colspan="1">79</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx58.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.7</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" rowspan="1" colspan="1">4.4</td></tr><tr><td align="left" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx59.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.9</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3.6</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx60.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.2</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.4</td></tr><tr><td align="left" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx61.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.8</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3.5</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx62.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.7</td><td align="center" rowspan="1" colspan="1">5.0</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">4.6</td></tr><tr><td align="left" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx63.jpg"/>
</td><td align="center" rowspan="1" colspan="1">4.6</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4.1</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="fchem-09-608438-fx64.jpg"/>
</td><td align="center" rowspan="1" colspan="1">5.7</td><td align="center" rowspan="1" colspan="1">&#x0003c;4.2</td><td align="center" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" rowspan="1" colspan="1">4.0</td></tr></tbody></table><table-wrap-foot><fn id="Tfn5"><label>a</label><p>All reported values are measured as duplicates and had a standard deviation less then &#x000b1;0.2.</p></fn><fn id="Tfn6"><label>b</label><p>Selectivity index was calculated as IC<sub>50</sub> MRC-5 cells divided by IC<sub>50</sub>
<italic>T. cruzi</italic>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s1-2"><title>Pharmacology and Parasitology</title><p>All compounds were tested for their trypanocidal activity against intracellular forms of <italic>T. cruzi</italic> (Tulahuen CL2, &#x003b2;-galactosidase strain (drug sensitive strain (discrete typing units, DTU VI)) as well as for cytotoxicity on MRC-5<sub>SV2</sub> cells (human lung fibroblasts). (<xref rid="B6" ref-type="bibr">Blaazer et al., 2014</xref>).</p></sec></sec><sec sec-type="results|discussion" id="s2"><title>Results and Discussion</title><p>In the previous work by Sijm <italic>et al.</italic>, the pyrazolone nitrogen was substituted with various (cyclo)-alkyl moieties resulting in the identification of NPD-0227 (<bold>3</bold>) as a potent (pIC<sub>50</sub> = 6.4) <italic>T. cruzi</italic> inhibitor with 100-fold selectivity over human MRC-5 cells (<xref rid="T1" ref-type="table">Table 1</xref>) (<xref rid="B24" ref-type="bibr">Sijm et al., 2019</xref>; <xref rid="B25" ref-type="bibr">Sijm et al., 2020</xref>). To further explore SAR and to investigate molecules with varying cLogPs, more polar and diverse substituents was explored.</p><p>Introduction of a carbonyl-alkyl moieties directly onto the pyrazolone nitrogen (<bold>6&#x02013;8</bold>, <xref rid="T1" ref-type="table">Table 1</xref>) resulted in weak inhibitors with pIC<sub>50</sub>&#x02019;s around 4.5. Similarly, introduction of sulphonyl-alkyl moieties such as dimethylsulfonamide (<bold>9</bold>) or sulphonylcyclopentyl (<bold>10</bold>) did not lead to inhibitors with pIC<sub>50</sub> values above 5.0. Epoxides were used to introduce &#x003b2;-alcohols on the pyrazolone ring resulting in compounds <bold>19</bold> and <bold>20</bold>. These alcohols also showed a large decrease in activity compared to NPD-0227 (pIC<sub>50</sub> = 6.4) with pIC<sub>50</sub>&#x02019;s of 4.4 and 5.1, respectively. Similarly, the introduction of ethyl-esters (<bold>21</bold>, <bold>22</bold>) resulted in decreased potencies compared to NPD-0227 with both compounds showing pIC<sub>50</sub> values of only 5.2.</p><p>While the substituents with a polar moiety (<bold>6</bold>&#x02013;<bold>10</bold>, <bold>19</bold>&#x02013;<bold>22</bold>, <xref rid="T1" ref-type="table">Table 1</xref>) showed decreased activities, as expected, introduction of more apolar moieties such as methyl-cyclohexyl (<bold>23</bold>) and pyrazole (<bold>24</bold>) showed moderate activity with pIC<sub>50</sub> values of 5.5. Introduction of more polar substituents attached to an aliphatic linker, such as imidazole <bold>25</bold> and morpholine <bold>26</bold> with cLogPs around 2.3 resulted in lower potencies (pIC<sub>50</sub> &#x0003c; 4.6). While the introduction of various oxadiazoles (<bold>33</bold>&#x02013;<bold>36</bold>) on this position yielded compounds with a more desirable cLogP&#x02019;s, this did not lead to very active compounds, with 1-propan-oxazole (<bold>34</bold>) showed the highest potency (pIC<sub>50</sub> = 5.2). As activities were generally close to the lower detection limit of the assay, selectivity indexes were quite low or defined as &#x0201c;bigger then&#x0201d;.</p><p>The initial attempts to introduce polar functional groups such as carbonyls, sulphonyls and alcohols close to the pyrazolone ring had a negative effect on their potency. One of the most potent compounds so far was methylcyclohexyl <bold>23</bold>, a bulky and apolar substituent. It was thought that introduction of a piperidine would introduce a similar sized moiety which would improve options to introduce polarity as a new handle to further modify.</p><p>This piperidine linker was first investigated by forming amides with corresponding acid chlorides or carboxylic acids, which led to analogues <bold>42</bold>&#x02013;<bold>47</bold> (<xref rid="T2" ref-type="table">Table 2</xref>). These groups introduced some polarity but these modifications did not lead to potent ligands (pIC50 &#x0003c; 5.3). Introducing sulphonamides instead of regular amides gave similar results as the majority showed moderately low activity (<bold>48</bold>&#x02013;<bold>54</bold>). Alkyl-sulphonamides with a cyclopropyl (<bold>49</bold>), isopropyl (<bold>50</bold>), dimethylamino (<bold>51</bold>) and cyclopentyl (<bold>52</bold>) all showed pIC<sub>50</sub>&#x02019;s around 5.1, while the smaller methyl substituted sulphonamide (<bold>48</bold>) had a slightly lower activity (pIC<sub>50</sub> = 4.5). Introduction of an aromatic ring on to the sulphonamide did not have a positive effect. Tosylate <bold>53</bold> (cLogP = 4.4) was inactive with a pIC<sub>50</sub> below 4.2. Introduction of an extra carbon between the sulphonamide and the benzene ring was successful as methylbenzyl <bold>54</bold> (cLogP = 3.8) showed a similar potency as NPD-0227 (<bold>3</bold>, <xref rid="T1" ref-type="table">Table 1</xref>) with a pIC<sub>50</sub> value of 6.2 and &#x0003e;100-fold selectivity over human MRC-5.</p><p>The boc-protected analogue <bold>40</bold> (cLogP = 3.6; pIC<sub>50</sub> = 5.9, <xref rid="T2" ref-type="table">Table 2</xref>) which was obtained during the synthesis of the free-amine building block showed that relatively large substituents are allowed on the piperidine linker, which was confirmed by sulphonamide <bold>54</bold>. The preference for larger, bulky substituents is also apparent with the urea linked analogues (<bold>55&#x02013;59</bold>). While the carbamide is inactive (<bold>55</bold>, cLogP = 1.6; pIC<sub>50</sub> = &#x0003c;4.2), introduction of larger apolar groups increased activity (<bold>57&#x02013;59</bold>), with the most potent compound being the 4-fluorophenyl <bold>59</bold> (pIC<sub>50</sub> = 5.9; cLogP = 4.0, 25-fold selectivity). The even more bulky disopropyl analogue (<bold>60</bold>), however, was totally inactive (pIC<sub>50</sub> &#x0003c; 4.2). Introduction of more polar substituents attached to the urea linker did not improve activity with pIC<sub>50</sub> values of &#x0003c;4.2 for ethylacetate derivative <bold>61</bold> (cLogP = 1.8) and 4.9 for the morpholine analogue (<bold>83</bold>, cLogP = 1.8). Two types of epoxides were used to introduce &#x003b2;-alcohols. While the aliphatic analogues <bold>62</bold>&#x02013;<bold>64</bold> (<xref rid="T3" ref-type="table">Table 3</xref>) showed low potencies (pIC<sub>50</sub> &#x0003c; 4.6), the aromatic derivatives (<bold>65</bold>&#x02013;<bold>66</bold>) showed micromolar activities with pIC<sub>50</sub> values of 5.6 and 5.7. Selectivity of the unsubstituted phenyl ring (<bold>65</bold>) was however a lot better than the 4-fluorophenyl (<bold>66</bold>).</p><p>As shown in <xref rid="T1" ref-type="table">Table 1</xref> and in previous work, aliphatic substituents on the dihydropyrazolone nitrogen led to the most potent compounds (<xref rid="B24" ref-type="bibr">Sijm et al., 2019</xref>). Introduction of aliphatic substituents on the piperidine nitrogen resulted in poor potencies, possibly caused by the introduction of a tertiary amine which can be protonated, as charged compounds are less likely to cross the cell membrane. The unsubstituted piperidine (<bold>41</bold>, cLogP = 2.3, <xref rid="T3" ref-type="table">Table 3</xref>) is totally inactive (pIC<sub>50</sub> &#x0003c; 4.2) and the alkylated analogues (<bold>67</bold>&#x02013;<bold>73</bold>) are not very active inhibitors (pIC<sub>50</sub> &#x0003c; 5.0). Analogues with an aromatic ring showed higher activities: the 2-furanylmethyl (<bold>74</bold>, cLogP = 3.5) and the 3-pyridineylmethyl (<bold>77</bold>, cLogP = 4.4) showed pIC<sub>50</sub> values of 5.0 and 5.3, respectively. The benzyl substituted piperidine <bold>75</bold> and the 4-pyridinemethyl <bold>78</bold> both showed pIC<sub>50</sub> values around 5.6, while 4-fluorobenzyl <bold>76</bold> (cLogP = 4.6) showed sub-micromolar potency with a pIC<sub>50</sub> of 6.1. Selectivity indexes of these compounds were moderate to poor, with the best compound, 4-pyridinemethyl <bold>78</bold> showing 16-fold selectivity toward <italic>T. cruzi</italic> over MRC-5 cells.</p><p>The final set of substituents on the piperidine linker were aromatic rings (<xref rid="T3" ref-type="table">Table 3</xref>, <bold>79</bold>&#x02013;<bold>82</bold>). This sub-series showed moderate activities with the 3-cyanophenyl (<bold>79</bold>), 4-methylbenzoate (<bold>81</bold>) and methyl-5-picolinate (<bold>82</bold>) all having low micromolar activities (pIC<sub>50</sub> = 5.7). The 3-pyridinyl analogue (<bold>80</bold>) was less active with a pIC<sub>50</sub> of 5.2. Best selectivity index was observed for 3-cyanophenyl <bold>79</bold> and methyl-5-picolinate <bold>82</bold>, which both had over 32-fold selectivity.</p><p>Overall, the introduction of polar moieties on the phenyl-dihydropyrazolones generally led to low activities against <italic>T. cruzi</italic>. Especially the introduction of a polar moiety directly next to the pyrazolone nitogen such as all carbonyl, sulphonyl and &#x003b2;-alcohol linked moieties (<bold>6</bold>&#x02013;<bold>10</bold>, <bold>19</bold>, <bold>20</bold>) resulted in analogues with low potencies. Introduction of aliphatic substituents or aromatic moieties resulted in interesting new anti-<italic>T. cruzi</italic> inhibitors with the best compounds <bold>54</bold> and <bold>76</bold> reaching sub micromolar potency. Installing a piperidine linker allowed for the introduction of a variety of substituents and it became apparent that aromatic moieties, either directly, with a methylene bridge or with a 2-atom linker performed best, showing pIC<sub>50</sub>&#x02019;s around 6.0.</p></sec><sec sec-type="conclusion" id="s3"><title>Conclusion</title><p>Our study results in valuable SAR data that has been obtained by introducing a variety of substituents on the dihydropyrazolone nitrogen atom. While decorating this position is synthetically very efficient and a wide variety of chemical functionalities are allowed, our studies did not lead to compounds that have a better activity than NPD-0227. Especially the piperidine linker opens a whole new range of options to introduce substituents and analogues reached low micromolar inhibitory activities against <italic>T. cruzi</italic>. The most active compounds were obtained if the piperidine is substituted with apolar moieties such as aryl or benzyl rings. Introduction of more polar substituents, such as imidazole <bold>25</bold> (cLogP = 2.3), succinimide <bold>46</bold> (cLogP = 0.9) and morpholine <bold>73</bold> (cLogP = 1.6) generally lead to compounds with high micromolar activities. The structural moiety performing best is a 2-atom linker followed by an aromatic moiety, of which sulphonamide <bold>54</bold> (cLogP = 3.8), urea <bold>59</bold> (cLogP = 4.0) and &#x003b2;-alcohols <bold>65</bold> and <bold>66</bold> (cLogP = 3.8/3.9) performed best. These molecules all have activities around 6.0 (pIC<sub>50</sub>) and especially sulphonamide <bold>54</bold> is promising with a pIC50 of 6.2 and &#x0003e;100-fold selectivity over MRC-5 cells. Also other aromatic substituents performed well, such as 4-fluorobenzyl (<bold>76</bold>), 3-cyanophenyl (<bold>79</bold>) and 5-methylnicotinate (<bold>82</bold>) show promising activities around 6.0, with <bold>79</bold> and <bold>82</bold> showing best selectivies (&#x0003e;32-fold) toward <italic>T. cruzi</italic>. While these results of this study are important in the design of novel &#x02018;drug leads&#x02019; for Chagas disease, the original goal, of identifying high potency molecules with a lower cLogP did not succeed. Most potent compounds with a cLogP below 2.0 were oxadiazole <bold>33</bold> and sulfamide <bold>51</bold>, which both showed a pIC<sub>50</sub> of 5.1.</p><sec id="s3-1"><title>Experimental Section Biology</title><p>
<italic>Trypanosoma cruzi in vitro assay.</italic> Bloodstream trypomastigotes of the Y strain of <italic>T. cruzi</italic> were obtained by cardiac puncture of infected Swiss Webster mice on the parasitaemia peak (<xref rid="B15" ref-type="bibr">Meirelles et al., 1986</xref>; <xref rid="B3" ref-type="bibr">Batista et al., 2010</xref>). For the standard <italic>in vitro</italic> susceptibility assay on intracellular amastigotes, <italic>T. cruzi</italic> Tulahuen CL2, &#x003b2;-galactosidase strain (nifurtimox-sensitive) was used. The strain is maintained on MRC-5<sub>SV2</sub> (human lung fibroblast) cells in MEM medium, supplemented with 200&#x000a0;mM L-glutamine, 16.5&#x000a0;mM NaHCO<sub>3</sub> and 5% inactivated fetal calf serum (FCSi). All cultures and assays were conducted at 37&#x000b0;C under an atmosphere of 5% CO<sub>2</sub>. Benznidazole was included in the assays as a positive control.</p><p>
<italic>MRC-5 cytotoxicity in vitro assay.</italic> MRC-5-<sub>SV2</sub> cells, originally from a human diploid lung cell line, were cultivated in MEM supplemented with L-glutamine (20&#x000a0;mM), 16.5&#x000a0;mM sodium hydrogen carbonate and 5% FCSi. For the assay, 10<sup>4</sup> cells/well were seeded onto the test plates containing the pre-diluted sample and incubated at 37&#x000b0;C and 5% CO<sub>2</sub> for 72&#x000a0;h. Cell viability was assessed fluorometrically 4&#x000a0;h after addition of resazurin (excitation 550&#x000a0;nm, emission 590&#x000a0;nm). The results are expressed as percentage reduction in cell viability compared to untreated controls. Tamoxifen was included in the assays as a positive control.</p><p>The use of laboratory rodents was carried out in strict accordance to all mandatory guidelines (EU directives, including the Revised Directive 2010/63/EU on the Protection of Animals used for Scientific Purposes that came into force on January 1, 2013, and the Declaration of Helsinki in its latest version).</p></sec><sec id="s3-2"><title>Experimental Section Chemistry</title><p>Chemicals and reagents were obtained from commercial suppliers and were used without further purification. Anhydrous DMF, THF, and DCM were obtained by passing them through an activated alumina column prior to use. Microwave reactions were executed using a Biotage<sup>&#x000ae;</sup> Initiator microwave system. <sup>1</sup>H NMR spectra were recorded on a Bruker Avance 250 (250&#x000a0;MHz), Bruker Avance 400 (400&#x000a0;MHz), Bruker Avance 500 (500&#x000a0;MHz) or Bruker 600 Avance (600&#x000a0;MHz) spectrometer. Data are reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, dd = double doublet, t = triplet, dt = double triplet, q = quartet, p = pentet, h = heptet, bs = broad singlet, m = multiplet), and coupling constants (Hz). Chemical shifts are reported in ppm with the natural abundance of deuterium in the solvent as the internal reference [CDCl<sub>3</sub>: &#x003b4; 7.26, (CD<sub>3</sub>)<sub>2</sub>SO: &#x003b4; 2.50]. <sup>13</sup>C NMR spectra were recorded on a Bruker Avance 500 (126&#x000a0;MHz) or Bruker Avance 600 (150&#x000a0;MHz). Chemical shifts are reported in ppm with the solvent resonance resulting from incomplete deuteration as the internal reference [CDCl<sub>3</sub>: &#x003b4; 77.16 or (CD<sub>3</sub>)<sub>2</sub>SO: &#x003b4; 39.52]. Systematic names for molecules according to IUPAC rules were generated using the Chemdraw AutoName program. LC-MS data was gathered using a Shimadzu HPLC/MS workstation with a LC-20AD pump system, SPD-M20A diode array detection, and a LCMS-2010&#x000a0;EV mass spectrometer. The column used is an Xbridge C18 5&#x000a0;&#x003bc;m column (100&#x000a0;mm &#x000d7; 4.6&#x000a0;mm). Solvents used were the following: solvent B = ACN, 0.1% formic Acid; solvent A = water, 0.1% formic acid. The analysis was conducted using a x?ow rate of 1.0&#x000a0;ml/min, start 5% B, linear gradient to 90% B in 4.5&#x000a0;min, then 1.5&#x000a0;min at 90% B, linear gradient to 5% B in 0.5&#x000a0;min and then 1.5&#x000a0;min at 5% B, total run time of 8&#x000a0;min. All reported compounds have purities &#x0003e;95%, measured at 254&#x000a0;nm, unless otherwise mentioned. All HRMS spectra were recorded on a Bruker micrOTOF mass spectrometer using ESI in positive-ion mode. In case of bromine containing molecules, the lowest peak of <sup>79</sup>Br was reported. Column puri?cations were either carried out automatically using Biotage equipment or manually, using 60&#x02013;200 mesh silica. TLC analyses were performed with Merck F254 alumina silica plates using UV visualization. All reactions were done under N<sub>2</sub> atmosphere, unless specifically mentioned. The cLogPs were calculated using CDD vault, CDD vault uses the ionic logP algorithm.</p></sec><sec id="s3-3"><title>Experimental Data</title><p>Compound <bold>5</bold>, <bold>6</bold>, <bold>15</bold>, <bold>23</bold>, <bold>27</bold>, <bold>29</bold>, <bold>33</bold>, <bold>38</bold>&#x02013;<bold>42</bold> and <bold>83</bold> are described below, other compounds can be found in the supporting information.</p><sec id="s3-3-1"><title>3-(4-Methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-1H-pyrazol-5(4H)-one (<bold>5</bold>)</title><p>Pyrazolone <bold>4</bold> (1.0&#x000a0;g, 3.4&#x000a0;mmol) and pyridin-3-ylboronic acid (0.62&#x000a0;g, 5.1&#x000a0;mmol) were charged to a microwave tube after which DME (12&#x000a0;ml) and 1&#x000a0;M Na<sub>2</sub>CO<sub>3</sub> (6.7&#x000a0;ml, 6.7&#x000a0;mmol) were added. The mixture was degassed with N<sub>2</sub> for 5&#x000a0;m after which Pd (dppf)Cl<sub>2</sub> (0.28&#x000a0;g, 34&#x000a0;mmol) was added. The reaction was heated at 120&#x000b0;C for 1&#x000a0;h in the microwave. The reaction mixture was diluted with EtOAc (30&#x000a0;ml) and filtered over Celite. The residue was washed with saturated NaHCO<sub>3</sub> (2&#x000a0;ml &#x000d7; 30&#x000a0;ml) and brine (1&#x000a0;ml &#x000d7; 30&#x000a0;ml). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated <italic>in vacuo.</italic> The remaining crude was purified over SiO<sub>2</sub> using a gradient of 50% EtOAc in heptane toward 5% MeOH in EtOAc to yield 700&#x000a0;mg (2.4&#x000a0;mmol, 70%) of the title compound as a white solid. <sup>1</sup>H NMR (500&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 11.50 (s, 1H), 8.69 (s, 1H), 8.55 (d, <italic>J</italic> = 3.8 Hz, 1H), 7.91 (apparent dt, <italic>J</italic> = 7.9, 1.9 Hz, 1H), 7.84 (dd, <italic>J</italic> = 8.7, 2.3 Hz, 1H), 7.73 (d, <italic>J</italic> = 2.3 Hz, 1H), 7.46 (dd, <italic>J</italic> = 7.9, 4.8 Hz, 1H), 7.22 (d, <italic>J</italic> = 8.8 Hz, 1H), 3.83 (s, 3H), 1.37 (s, 6H). <sup>13</sup>C NMR (126&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 181.1, 161.6, 157.7, 150.0, 148.6, 137.1, 133.7, 128.1, 128.0, 127.4, 124.4, 123.8, 112.4, 56.3, 46.9, 22.5. LC-MS (ESI) <italic>m</italic>/<italic>z</italic> found: 296 (M + H)<sup>+</sup>; retention time: 2.67&#x000a0;min. HRMS-ESI (M + H)<sup>+</sup> calculated for C<sub>17</sub>H<sub>18</sub>N<sub>3</sub>O<sub>2</sub>: 296.1394, found: 296.1391.</p></sec><sec id="s3-3-2"><title>1-(cyclopropanecarbonyl)-3-(4-Methoxy-3-(Pyridin-3-Yl)phenyl)-4,4-Dimethyl-1h-Pyrazol-5(4H)-One (<bold>6</bold>)</title><p>Pyrazolone <bold>5</bold> (50&#x000a0;mg, 0.17&#x000a0;mmol) was dissolved in DMF (2&#x000a0;ml) and sodium hydride (60% in mineral oil) (10&#x000a0;mg, 0.25&#x000a0;mmol) was added. After stirring for 30&#x000a0;min cyclopropanecarbonyl chloride (20&#x000a0;mg, 0.19&#x000a0;mmol) was added and the mixture was stirred at rt for 18&#x000a0;h after which the reaction was quenched with water (25&#x000a0;ml) and extracted with EtOAc (25&#x000a0;ml). The organic layer was washed with sat. aq. NaHCO<sub>3</sub> (2&#x000a0;ml &#x000d7; 20&#x000a0;ml), brine (20&#x000a0;ml) and dried over MgSO<sub>4</sub> after which volatiles were evaporated yielding 24&#x000a0;mg (0.07&#x000a0;mmol, 39%) of the title compound as a white solid. <sup>1</sup>H NMR (500&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.76 (d, <italic>J</italic> = 2.0 Hz, 1H), 8.60 (dd, <italic>J</italic> = 4.8, 1.7 Hz, 1H), 7.95&#x02013;7.84 (m, 3H), 7.38 (dd, <italic>J</italic> = 7.8, 4.8 Hz, 1H), 7.09&#x02013;7.03 (m, 1H), 3.89 (s, 3H), 3.05&#x02013;2.97 (m, 1H), 1.61 (s, 6H), 1.32&#x02013;1.25 (m, 2H), 1.11&#x02013;1.02 (m, 2H). <sup>13</sup>C NMR (126&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 178.0, 171.9, 162.3, 158.7, 150.0, 148.3, 137.1, 133.3, 129.5, 128.7, 127.8, 123.1, 122.9, 111.2, 55.8, 49.9, 23.2, 13.5, 11.3. LC-MS (ESI) <italic>m</italic>/<italic>z</italic> found: 364 (M + H)<sup>+</sup>; retention time: 3.43&#x000a0;min. HRMS-ESI (M + H)<sup>+</sup> calculated for C<sub>21</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub>: 364.1656, found: 364.1653.</p></sec><sec id="s3-3-3"><title>Ethyl 2-(3-(3-bromo-4-methoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)acetate (<bold>13</bold>)</title><p>Pyrazolone <bold>4</bold> (5.0&#x000a0;g, 16.8&#x000a0;mmol) was dissolved in DMF (35&#x000a0;ml) and sodium hydride (60% in mineral oil) (0.49&#x000a0;g, 20.2&#x000a0;mmol) was added. After stirring for 30&#x000a0;min ethyl 2-bromoacetate (2.23&#x000a0;ml, 20.2&#x000a0;mmol) was added and the mixture was heated to 50&#x000b0;C for 3&#x000a0;h after which the reaction was quenched with water (250&#x000a0;ml). Solids were filtered off and dried <italic>in vacuo</italic>, yielding 5.6&#x000a0;g (14.6&#x000a0;mmol, 87%) of the title compound as a white solid. <sup>1</sup>H NMR (500&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.05 (d, <italic>J</italic> = 2.2 Hz, 1H), 7.70 (dd, <italic>J</italic> = 8.6, 2.2 Hz, 1H), 6.93 (d, <italic>J</italic> = 8.7 Hz, 1H), 4.55 (s, 2H), 4.23 (q, <italic>J</italic> = 7.1 Hz, 2H), 3.95 (s, 3H), 1.53 (s, 6H), 1.29 (t, <italic>J</italic> = 7.1 Hz, 3H). <sup>13</sup>C NMR (126&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 179.1, 167.8, 160.9, 157.2, 131.4, 126.7, 124.6, 112.3, 111.5, 61.7, 56.4, 48.1, 45.8, 22.5, 14.1. LC-MS (ESI) <italic>m</italic>/<italic>z</italic> found: 383 (M + H)<sup>+</sup>; retention time: 4.75&#x000a0;min. HRMS-ESI (M + H)<sup>+</sup> calculated for C<sub>16</sub>H<sub>20</sub>BrN<sub>2</sub>O<sub>4</sub>: 383.0601, found: 383.0588.</p></sec><sec id="s3-3-4"><title>3-(3-Bromo-4-methoxyphenyl)-1-(cyclohexylmethyl)-4,4-dimethyl-1H-pyrazol-5(4H)-one (<bold>15</bold>)</title><p>Pyrazolone <bold>4</bold> (100&#x000a0;mg, 0.30&#x000a0;mmol) was dissolved in DMF (3&#x000a0;ml) and sodium hydride (60% in mineral oil) (15&#x000a0;mg, 0.38&#x000a0;mmol) was added. After stirring for 30&#x000a0;min (bromomethyl)cyclohexane (63&#x000a0;mg, 0.67&#x000a0;mmol) was added and the mixture was stirred at rt for 18&#x000a0;h after which the reaction was quenched with water (25&#x000a0;ml) and extracted with EtOAc (25&#x000a0;ml). The organic layer was washed with brine (2&#x000a0;ml &#x000d7; 20&#x000a0;ml) and dried over MgSO<sub>4</sub> after which volatiles were evaporated yielding 105&#x000a0;mg (0.27&#x000a0;mmol, 91%) of the title compound as a transparent oil. <sup>1</sup>H NMR (500&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.03 (d, <italic>J</italic> = 2.2 Hz, 1H), 7.66 (dd, <italic>J</italic> = 8.6, 2.2 Hz, 1H), 6.90 (d, <italic>J</italic> = 8.7 Hz, 1H), 3.92 (s, 3H), 3.56 (d, <italic>J</italic> = 7.2 Hz, 2H), 1.89&#x02013;1.80 (m, 1H), 1.74&#x02013;1.68 (m, 2H), 1.67&#x02013;1.61 (m, 3H), 1.45 (s, 6H), 1.28&#x02013;1.13 (m, 5H), 1.08&#x02013;0.89 (m, 2H). <sup>13</sup>C NMR (126&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 178.6, 160.1, 156.9, 131.2, 126.5, 125.0, 112.3, 111.5, 56.4, 50.3, 48.3, 36.9, 30.5, 26.4, 25.7, 22.8. LC-MS (ESI) <italic>m</italic>/<italic>z</italic> found: 393 (M + H)<sup>+</sup>; retention time: 6.05&#x000a0;min. HRMS-ESI (M + H)<sup>+</sup> calculated for C<sub>19</sub>H<sub>26</sub>BrN<sub>2</sub>O<sub>2</sub>: 393.1172, found: 393.1156.</p></sec><sec id="s3-3-5"><title>1-(cyclohexylmethyl)-3-(4-Methoxy-3-(Pyridin-3-Yl)phenyl)-4,4-Dimethyl-1h-Pyrazol-5(4H)-One (<bold>23</bold>)</title><p>Pyrazolone <bold>15</bold> (100&#x000a0;mg, 0.16&#x000a0;mmol) and pyridin-3-ylboronic acid (47&#x000a0;mg, 0.38&#x000a0;mmol) were charged to a microwave tube after which DME (3&#x000a0;ml) and 1&#x000a0;M Na<sub>2</sub>CO<sub>3</sub> (0.8&#x000a0;ml, 0.8&#x000a0;mmol) were added. The mixture was degassed with N<sub>2</sub> for 5&#x000a0;m after which Pd (dppf) Cl<sub>2</sub> (21&#x000a0;mg, 25&#x000a0;&#x000b5;mol) was added. The reaction was heated at 120&#x000b0;C for 1&#x000a0;h in the microwave. The reaction mixture was diluted with EtOAc (30&#x000a0;ml) and filtered over Celite. The residue was washed with saturated NaHCO<sub>3</sub> (2&#x000a0;ml &#x000d7; 30&#x000a0;ml) and brine (1&#x000a0;ml &#x000d7; 30&#x000a0;ml). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated <italic>in vacuo.</italic> The remaining crude was purified over SiO<sub>2</sub> using a gradient of 50% EtOAc in heptane toward 100% EtOAc to yield 64&#x000a0;mg (0.16&#x000a0;mmol, 64%) of the title compound as a white solid. <sup>1</sup>H NMR (500&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.78 (d, <italic>J</italic> = 2.1 Hz, 1H), 8.59 (d, <italic>J</italic> = 4.8 Hz, 1H), 7.88 (apparent dt, <italic>J</italic> = 7.8, 1.9 Hz, 1H), 7.82 (d, <italic>J</italic> = 2.2 Hz, 1H), 7.77 (dd, <italic>J</italic> = 8.6, 2.2 Hz, 1H), 7.37 (dd, <italic>J</italic> = 7.9, 4.9 Hz, 1H), 7.03 (d, <italic>J</italic> = 8.6 Hz, 1H), 3.87 (s, 3H), 3.58 (d, <italic>J</italic> = 7.2 Hz, 2H), 2.05&#x02013;1.79 (m, 2H), 1.76&#x02013;1.60 (m, 5H), 1.50 (s, 6H), 1.29&#x02013;1.10 (m, 3H), 1.06&#x02013;0.95 (m, 2H). <sup>13</sup>C NMR (126&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 178.7, 161.0, 157.8, 150.1, 148.2, 137.0, 133.6, 128.7, 127.6, 127.5, 124.2, 123.1, 111.1, 55.8, 50.3, 48.4, 36.9, 30.5, 26.4, 25.7, 22.9. LC-MS (ESI) <italic>m</italic>/<italic>z</italic> found: 392 (M + H)<sup>+</sup>; retention time: 4.54&#x000a0;min. HRMS-ESI (M + H)<sup>+</sup> calculated for C<sub>24</sub>H<sub>30</sub>N<sub>3</sub>O<sub>2</sub>: 392.2333, found: 392.2319.</p></sec><sec id="s3-3-6"><title>2-(3-(3-bromo-4-methoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)acetohydrazide (<bold>27</bold>)</title><p>Ester <bold>13</bold> (1.5&#x000a0;g, 3.91&#x000a0;mmol) was refluxed in hydrazine monohydrate (1.89&#x000a0;ml, 39.1&#x000a0;mmol) and ethanol (25&#x000a0;ml) for 18&#x000a0;h. After that the mixture was allowed to cool down, the mixture was concentrated and 20&#x000a0;ml of water was added. The solids were filtered off and dried <italic>in vacuo</italic> yielding 1.36&#x000a0;g (3.7&#x000a0;mmol, 94%) of the title compound as a white solid. <sup>1</sup>H NMR (500&#x000a0;MHz, DMSO-<italic>d</italic>6) &#x003b4; 9.29 (s, 1H), 7.96 (s, 1H), 7.79 (d, <italic>J</italic> = 8.6 Hz, 1H), 7.17 (d, <italic>J</italic> = 8.6 Hz, 1H), 4.29 (d, <italic>J</italic> = 13.2 Hz, 4H), 3.90 (s, 3H), 1.39 (s, 6H). <sup>13</sup>C NMR (126&#x000a0;MHz, DMSO-d<sub>6</sub>) &#x003b4; 178.9, 166.4, 160.0, 157.0, 130.5, 127.6, 124.6, 113.1, 111.8, 56.9, 47.7, 45.9, 22.4. LC-MS (ESI) <italic>m</italic>/<italic>z</italic> found:369 (M + H)<sup>+</sup>; retention time: 3.59&#x000a0;min.</p></sec><sec id="s3-3-7"><title>1-((1,3,4-Oxadiazol-2-yl)methyl)-3-(3-bromo-4-methoxyphenyl)-4,4-dimethyl-1H-pyrazol-5(4H)-one (<bold>29</bold>)</title><p>Hydrazide <bold>27</bold> (200&#x000a0;mg, 0.54&#x000a0;mmol) was stirred in triethylorthoformate (0.9&#x000a0;ml, 5.4&#x000a0;mmol) and PTSA (10.30&#x000a0;mg, 0.054&#x000a0;mmol) was added. The mixture was heated at 80&#x000b0;C for 18&#x000a0;h after which the volatiles were evaporated and the resulting crude was purified over SiO<sub>2</sub> using a gradient of 20% EtOAc in heptane toward 80% EtOAc in heptane. This yielded 70&#x000a0;mg (0.19&#x000a0;mmol, 34%) of the title compound as a white solid. <sup>1</sup>H NMR (500&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.42 (s, 1H), 7.99 (d, <italic>J</italic> = 2.2 Hz, 1H), 7.66 (dd, <italic>J</italic> = 8.7, 2.2 Hz, 1H), 6.90 (d, <italic>J</italic> = 8.7 Hz, 1H), 5.22 (s, 2H), 3.92 (s, 3H), 1.52 (s, 6H). <sup>13</sup>C NMR (126&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 178.5, 161.9, 161.6, 157.4, 153.6, 131.4, 126.9, 124.2, 112.3, 111.6, 56.4, 48.1, 39.0, 22.6. LC-MS (ESI) <italic>m</italic>/<italic>z</italic> found: 397 (M + H)<sup>+</sup>; retention time: 4.27&#x000a0;min. HRMS-ESI (M + H)<sup>+</sup> calculated for C<sub>15</sub>H<sub>16</sub>BrN<sub>4</sub>O<sub>3</sub>: 379.0400, found: 379.0391.</p></sec><sec id="s3-3-8"><title>1-((1,3,4-Oxadiazol-2-yl)methyl)-3-(4-methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-1H-pyrazol-5(4H)-one (<bold>33</bold>)</title><p>Pyrazolone <bold>29</bold> (50&#x000a0;mg, 0.13&#x000a0;mmol) and pyridin-3-ylboronic acid (24&#x000a0;mg, 0.38&#x000a0;mmol) were charged to a microwave tube after which DME (3&#x000a0;ml) and 1&#x000a0;M Na<sub>2</sub>CO<sub>3</sub> (0.5&#x000a0;ml, 0.5&#x000a0;mmol) were added. The mixture was degassed with N<sub>2</sub> for 5&#x000a0;m after which Pd (dppf) Cl<sub>2</sub> (11&#x000a0;mg, 13&#x000a0;&#x000b5;mol) was added. The reaction was heated at 120&#x000b0;C for 1&#x000a0;h in the microwave. The reaction mixture was diluted with EtOAc (30&#x000a0;ml) and filtered over Celite. The residue was washed with saturated NaHCO<sub>3</sub> (2&#x000a0;ml &#x000d7; 30&#x000a0;ml) and brine (1&#x000a0;ml &#x000d7; 30&#x000a0;ml). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated <italic>in vacuo.</italic> The remaining crude was purified over SiO<sub>2</sub> using a gradient of 50% EtOAc in heptane toward 100% EtOAc to yield 36&#x000a0;mg (0.10&#x000a0;mmol, 72%) of the title compound as a white solid. <sup>1</sup>H NMR (500&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.79 (s, 1H), 8.61 (s, 1H), 8.41 (s, 1H), 7.95&#x02013;7.83 (m, 1H), 7.83&#x02013;7.73 (m, 2H), 7.41 (s, 1H), 7.03 (d, <italic>J</italic> = 8.4 Hz, 1H), 5.23 (s, 2H), 3.87 (s, 3H), 1.56 (s, 6H). <sup>13</sup>C NMR (126&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 178.6, 162.4, 162.0, 158.2, 153.6, 149.5, 147.6, 137.5, 133.9, 128.9, 128.0, 127.4, 123.4, 111.2, 55.9, 48.2, 39.0, 22.8. LC-MS (ESI) <italic>m</italic>/<italic>z</italic> found: 378 (M + H)<sup>+</sup>; retention time: 2.93&#x000a0;min. HRMS-ESI (M + H)<sup>+</sup> calculated for C<sub>20</sub>H<sub>20</sub>N<sub>5</sub>O<sub>3</sub>: 378.1562, found: 378.1562.</p></sec><sec id="s3-3-9"><title>3-(3-Bromo-4-methoxyphenyl)-4,4-dimethyl-1-(piperidin-4-yl)-1H-pyrazol-5(4H)-one (<bold>38</bold>)</title><p>Keto-ester <bold>37</bold> (32&#x000a0;g, 102&#x000a0;mmol) was dissolved in methanol (200&#x000a0;ml) and stirred. To this solution 4-hydrazinylpiperidine dihydrochloride (76&#x000a0;g, 406&#x000a0;mmol) dissolved in Water (80&#x000a0;ml) was added. The mixture was refluxed for 72&#x000a0;h after which 150&#x000a0;ml water was added and MeOH was removed <italic>in vacuo</italic>. To the remaining solution 10&#x000a0;M NaOH was added slowly until the pH was &#x0223c;13. Solids were collected and washed with water (20&#x000a0;ml) to yield 31&#x000a0;g (82&#x000a0;mmol, 80%) of the title compound. <sup>1</sup>H NMR (500&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.00 (d, <italic>J</italic> = 2.2 Hz, 1H), 7.78 (dd, <italic>J</italic> = 8.6, 2.2 Hz, 1H), 7.16 (d, <italic>J</italic> = 8.8 Hz, 1H), 4.06&#x02013;3.94 (m, 1H), 3.90 (s, 3H), 3.04&#x02013;2.93 (m, 2H), 2.53&#x02013;2.51 (m, 2H), 1.84&#x02013;1.75 (m, 2H), 1.66&#x02013;1.56 (m, 2H), 1.35 (s, 6H). <sup>13</sup>C NMR (126&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 177.5, 159.7, 156.9, 130.4, 127.4, 124.8, 113.1, 111.9, 56.9, 51.5, 48.4, 45.6, 31.7, 22.4. LC-MS (ESI) <italic>m</italic>/<italic>z</italic> found: 380 (M + H)<sup>+</sup>; retention time: 3.19&#x000a0;min. HRMS-ESI (M + H)<sup>+</sup> calculated for C<sub>17</sub>H<sub>23</sub>BrN<sub>3</sub>O<sub>2</sub>: 380.0968, found: 380.0968.</p></sec><sec id="s3-3-10"><title>Tert-butyl 4-(3-(3-bromo-4-methoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)piperidine-1-carboxylate (<bold>39</bold>)</title><p>Piperidine <bold>38</bold> (25&#x000a0;g, 65.7&#x000a0;mmol) was added to a round-bottom flask after which DCM (500&#x000a0;ml) was added, followed by di-tert-butyl dicarbonate (15.6&#x000a0;ml, 67.1&#x000a0;mmol) and triethylamine (9.4&#x000a0;ml, 67.1&#x000a0;mmol). The reaction mixture was extracted with water (2&#x000a0;ml &#x000d7; 400&#x000a0;ml) and brine (400&#x000a0;ml) and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>. Solids were filtered off and volatiles were evaporated yielding 28&#x000a0;g (58&#x000a0;mmol, 89%) of the title compound as a light-brown solid. <sup>1</sup>H NMR (500&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.05 (d, <italic>J</italic> = 2.1 Hz, 1H), 7.70 (dd, <italic>J</italic> = 8.7, 2.2 Hz, 1H), 6.94 (d, <italic>J</italic> = 8.6 Hz, 1H), 4.31&#x02013;4.20 (m, 3H), 3.96 (s, 3H), 2.87 (t, <italic>J</italic> = 12.9 Hz, 2H), 2.03 (apparent qd, <italic>J</italic> = 12.5, 4.5 Hz, 2H), 1.83&#x02013;1.78 (m, 2H), 1.51 (s, 9H), 1.48 (s, 6H). LC-MS (ESI) <italic>m</italic>/<italic>z</italic> found: 424 (M + H, -t-Bu)<sup>+</sup>; retention time: 5.34&#x000a0;min. HRMS-ESI (M + H)<sup>+</sup> calculated for C<sub>22</sub>H<sub>31</sub>N<sub>3</sub>O<sub>4</sub>: 480.1492, found: 480.1477.</p></sec><sec id="s3-3-11"><title>Tert-butyl 4-(3-(4-methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)piperidine-1-carboxylate (<bold>40</bold>)</title><p>Boc-protected piperidine <bold>39</bold> (25.2&#x000a0;g, 52.5&#x000a0;mmol) and pyridin-3-ylboronic acid (9.0&#x000a0;g, 73&#x000a0;mmol) were charged to a round-bottom flask after which DME (400&#x000a0;ml) and 1&#x000a0;M Na<sub>2</sub>CO<sub>3</sub> (210&#x000a0;ml, 210&#x000a0;mmol) were added. The mixture was degassed with N<sub>2</sub> for 15&#x000a0;m after which Pd (dppf) Cl<sub>2</sub> (2.1&#x000a0;g, 2.6&#x000a0;mmol) was added. The reaction was heated at 80&#x000b0;C for 16&#x000a0;h. The reaction mixture was diluted with MTBE (500&#x000a0;ml) and filtered over Celite. The residue was washed with saturated NaHCO<sub>3</sub> (2&#x000a0;ml &#x000d7; 600&#x000a0;ml) and brine (1&#x000a0;ml &#x000d7; 600&#x000a0;ml). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated <italic>in vacuo</italic> to yield 21.5&#x000a0;g (44.9&#x000a0;mmol, 86%) of the title compound. <sup>1</sup>H NMR (500&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.75 (s, 1H), 8.56 (d, <italic>J</italic> = 4.0 Hz, 1H), 7.84 (d, <italic>J</italic> = 7.9 Hz, 1H), 7.78 (d, <italic>J</italic> = 2.0 Hz, 1H), 7.75 (dd, <italic>J</italic> = 8.6, 2.1 Hz, 1H), 7.35 (dd, <italic>J</italic> = 7.7, 4.9 Hz, 1H), 7.01 (d, <italic>J</italic> = 8.7 Hz, 1H), 4.33&#x02013;4.08 (m, 3H), 3.85 (s, 3H), 2.82 (s, 2H), 1.99 (apparent q, <italic>J</italic> = 11.2 Hz, 2H), 1.76 (d, <italic>J</italic> = 11.6 Hz, 2H), 1.47 (s, 7H), 1.45 (s, 9H). <sup>13</sup>C NMR (126&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 178.0, 161.2, 157.8, 154.7, 150.1, 148.3, 136.8, 133.5, 128.7, 127.7, 127.5, 124.0, 123.1, 111.1, 79.7, 55.8, 50.8, 48.8, 30.0, 28.4, 22.7. LC-MS (ESI) <italic>m</italic>/<italic>z</italic> found: 479 (M + H)<sup>+</sup>; retention time: 4.03&#x000a0;min. HRMS-ESI (M + H)<sup>+</sup> calculated for C<sub>27</sub>H<sub>35</sub>N<sub>4</sub>O<sub>4</sub>: 479.2653, found: 479.2651.</p></sec><sec id="s3-3-12"><title>3-(4-Methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-1-(piperidin-4-yl)-1H-pyrazol-5(4H)-one Hydrochloride (<bold>41</bold>)</title><p>Boc-protected piperidine <bold>40</bold> (25.1&#x000a0;g, 52.4&#x000a0;mmol) was dissolved in dioxane (100&#x000a0;ml) and hydrogen chloride in dioxane (4&#x000a0;N) (131&#x000a0;ml, 524&#x000a0;mmol) was added in portions. The reaction was stirred for 40&#x000a0;h after which volatiles were evaporated. Attempts were made to recrystallize the resulting dark-oil from MTBE, iPr-OH, iPr-OH:H<sub>2</sub>O to no avail. The crude was redissolved in EtOAc (800&#x000a0;ml) and extracted with aq. sat. Na<sub>2</sub>CO<sub>3</sub> (2&#x000a0;ml &#x000d7; 500&#x000a0;ml) and brine (500&#x000a0;ml). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and volatiles were evaporated. Attempts to recrystallize from i-PrOH or iPrOH:H2O were again unsuccessful. Evaporation of i-PrOH:H<sub>2</sub>O ultimately yielded 16.7&#x000a0;g (44.1&#x000a0;mmol, 84%) of the title compound as a light brown powder. <sup>1</sup>H NMR (500&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.70&#x02013;8.67 (m, 1H), 8.56 (dd, <italic>J</italic> = 4.9, 1.6 Hz, 1H), 7.91 (apparent dt, <italic>J</italic> = 8.0, 1.9 Hz, 1H), 7.85 (dd, <italic>J</italic> = 8.7, 1.9 Hz, 1H), 7.76 (d, <italic>J</italic> = 1.8 Hz, 1H), 7.47 (dd, <italic>J</italic> = 7.7, 4.9 Hz, 1H), 7.23 (d, <italic>J</italic> = 8.8 Hz, 1H), 4.08&#x02013;3.96 (m, 1H), 3.84 (s, 3H), 3.00 (d, <italic>J</italic> = 12.3 Hz, 2H), 2.58&#x02013;2.51 (m, 2H), 1.81 (apparent qd, <italic>J</italic> = 12.3, 4.1 Hz, 2H), 1.68&#x02013;1.58 (m, 2H), 1.39 (s, 6H). <sup>13</sup>C NMR (126&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 177.2, 160.3, 157.5, 149.7, 149.6, 148.3, 148.2, 136.7, 133.2, 127.8, 127.2, 123.5, 123.4, 112.0, 55.9, 51.0, 48.0, 45.2, 31.2, 22.2. LC-MS (ESI) <italic>m</italic>/<italic>z</italic> found: 379 (M + H)<sup>+</sup>; retention time: 2.40&#x000a0;min. HRMS-ESI (M + H)<sup>+</sup> calculated for C<sub>22</sub>H<sub>27</sub>N<sub>4</sub>O<sub>2</sub>: 379.2129, found: 379.2121.</p></sec><sec id="s3-3-13"><title>1-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-(4-methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-1H-pyrazol-5(4H)-one (<bold>42</bold>)</title><p>Amine <bold>41</bold> (100&#x000a0;mg, 0.26&#x000a0;mmol) was stirred with sodium hydride (60% in mineral oil) (16&#x000a0;mg, 0.40&#x000a0;mmol) in DMF (1&#x000a0;ml). After 30&#x000a0;min cyclopropanecarbonyl chloride (0.026&#x000a0;ml, 0.29&#x000a0;mmol) was added. The reaction was stirred for 2&#x000a0;h after which the reaction was quenched with water (20&#x000a0;ml) and extracted with EtOAc (20&#x000a0;ml). The organic layer was washed with sat. aq. NaHCO<sub>3</sub> solution (2&#x000a0;ml &#x000d7; 20&#x000a0;ml), brine (20&#x000a0;ml) and dried over MgSO<sub>4</sub>. Volatiles were evaporated and the remaining crude was purified over SiO<sub>2</sub> using a gradient of 50% EtOAc in heptane toward 5% MeOH in EtOAc, yielding 45&#x000a0;mg (0.10&#x000a0;mmol, 38%) of the title compound as a white solid. <sup>1</sup>H NMR (500&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.78 (s, 1H), 8.60 (d, <italic>J</italic> = 4.0 Hz, 1H), 7.89 (d, <italic>J</italic> = 7.9 Hz, 1H), 7.80 (d, <italic>J</italic> = 2.2 Hz, 1H), 7.77 (dd, <italic>J</italic> = 8.6, 2.2 Hz, 1H), 7.41 (dd, <italic>J</italic> = 7.7, 4.9 Hz, 1H), 7.03 (d, <italic>J</italic> = 8.7 Hz, 1H), 4.75 (d, <italic>J</italic> = 12.9 Hz, 1H), 4.41&#x02013;4.29 (m, 2H), 3.88 (s, 3H), 3.24 (t, <italic>J</italic> = 12.7 Hz, 1H), 2.72 (apparent t, <italic>J</italic> = 12.4 Hz, 1H), 2.14&#x02013;1.74 (m, 7H), 1.50 (s, 6H), 1.05&#x02013;0.95 (m, 2H), 0.77 (dd, <italic>J</italic> = 7.9, 3.5 Hz, 2H). <sup>13</sup>C NMR (126&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 178.0, 171.9, 161.3, 157.8, 149.8, 148.0, 137.2, 133.7, 128.7, 127.6, 127.5, 124.0, 123.3, 111.2, 55.8, 50.7, 48.8, 44.7, 41.4, 30.8, 29.7, 22.8, 11.1, 7.5, 7.4. LC-MS (ESI) <italic>m</italic>/<italic>z</italic> found: 447 (M + H)<sup>+</sup>; retention time: 3.20&#x000a0;min. HRMS-ESI (M + H)<sup>+</sup> calculated for C<sub>26</sub>H<sub>31</sub>N<sub>4</sub>O<sub>3</sub>: 447.2391, found: 447.2390.</p></sec><sec id="s3-3-14"><title>3-(4-Methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-1-(1-(morpholine-4-carbonyl)piperidin-4-yl)-1H-pyrazol-5(4H)-one (<bold>83</bold>)</title><p>Amine <bold>41</bold> (400&#x000a0;mg, 1.1&#x000a0;mmol) was dissolved in dioxane (15&#x000a0;ml) and 25&#x000a0;ml of saturated NaHCO<sub>3</sub> was added followed by a dropwise addition of a 4-nitrophenyl chloroformate (639&#x000a0;mg, 3.2&#x000a0;mmol) in dioxane (10&#x000a0;ml) solution. The reaction mixture was stirred for 22&#x000a0;h, diluted with EtOAc and washed with a saturated sodium bicarbonate solution. The organic fraction was dried with brine, evaporated to dryness in the presence of SiO<sub>2</sub> and purified over the same medium using 1:3 EtOAc:c-hexane with 1% TEA toward 100% EtOAc with 1% TEA. After confirming identify of the product by semi-crude NMR it was used in the following step. K<sub>2</sub>CO<sub>3</sub> (25&#x000a0;mg, 0.18&#x000a0;mmol) and morpholine (0.016&#x000a0;ml, 0.18&#x000a0;mmol) were dissolved in DMF (5&#x000a0;ml) to which the earlier isolated intermediate (50&#x000a0;mg, 0.092&#x000a0;mmol) was added. This reaction mixture was stirred at room temperature for 4&#x000a0;days and an additional equivalent morpholine (0.016&#x000a0;ml, 0.18&#x000a0;mmol) was added after 2&#x000a0;days. The reaction mixture was diluted with EtOAc (25&#x000a0;ml) and washed with sat. aq. Na<sub>2</sub>CO<sub>3</sub> (25&#x000a0;ml). The aqueous layer was back extracted with EtOAc (25&#x000a0;ml) and the combined organic layers were washed with brine (25&#x000a0;ml), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated <italic>in vacuo</italic>. The remaining crude was coated on SiO<sub>2</sub> and purified over SiO<sub>2</sub> using a gradient from EtOAc (1% TEA): cyclohexane 1:1 (v/v) toward 1% MeOH in EtOAc (1% TEA), evaporation of volatiles yielded a colourless oil which was re-dissolved in DCM and concentrated to afford 19&#x000a0;mg (0.039&#x000a0;mmol, 43%). <sup>1</sup>H NMR (600&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.83&#x02013;8.78 (m, 1H), 8.62&#x02013;8.59 (m, 1H), 8.04&#x02013;7.98 (m, 1H), 7.82 (d, <italic>J</italic> = 2.2 Hz, 1H), 7.77 (dd, <italic>J</italic> = 8.7, 2.2 Hz, 1H), 7.49 (dd, <italic>J</italic> = 7.8, 5.1 Hz, 1H), 7.03 (d, <italic>J</italic> = 8.7 Hz, 1H), 4.29&#x02013;4.23 (m, 1H), 3.87 (s, 3H), 3.85&#x02013;3.80 (m, 2H), 3.70&#x02013;3.63 (m, 4H), 3.31&#x02013;3.25 (m, 4H), 2.94&#x02013;2.83 (m, 2H), 2.10&#x02013;2.02 (m, 2H), 1.85&#x02013;1.78 (m, 2H), 1.49 (s, 6H). <sup>13</sup>C NMR (151&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 178.0, 163.9, 161.1, 157.8, 148.5, 146.5, 138.5, 134.4, 128.7, 128.0, 126.9, 124.2, 123.7, 111.2, 66.7, 55.8, 51.0, 48.8, 47.4, 46.1, 30.0, 22.7. LC-MS (ESI) <italic>m/z</italic> found: 492 (M + H)<sup>+</sup>; retention time: 3.07&#x000a0;min. HRMS-ESI (M + H)<sup>+</sup> calculated for C<sub>27</sub>H<sub>34</sub>N<sub>5</sub>O<sub>4</sub>
<sup>+</sup>: 492.2605, found 492.2615.</p></sec></sec></sec></body><back><ack><p>Authors would like to thank D. Ahrens, A. Chen, M. Roseboom, J. Teeken H. Custers for technical assistance and M. Wijtmans for valuable advice.</p></ack><sec sec-type="data-availability" id="s4"><title>Data Availability Statement</title><p>The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.</p></sec><sec id="s5"><title>Author Contributions</title><p>MS contributed to the synthesis of the molecules, LM and GC did the parasitological screenings, MS, GS, IE, and RL were involved in the design of the molecules, LM, IE, and RL were responsible for obtaining the required funding, the manuscript was written by MS, GS, and RL and all authors made corrections and gave feedback to the manuscript.</p></sec><sec id="s6"><title>Funding</title><p>The PDE4NPD project was funded by the European Union under the FP-7-Health program, project ID: 602,666.</p></sec><sec sec-type="COI-statement" id="s7"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alpern</surname><given-names>J. D.</given-names></name><name><surname>Lopez-Velez</surname><given-names>R.</given-names></name><name><surname>Stauffer</surname><given-names>W. M.</given-names></name></person-group> (<year>2017</year>). <article-title>Access to Benznidazole for Chagas Disease in the United States&#x02014;Cautious Optimism?</article-title>
<source>PLoS Negl. Trop. Dis.</source>
<volume>11</volume>, <fpage>e0005794</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0005794</pub-id>
<pub-id pub-id-type="pmid">28910299</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Basore</surname><given-names>K.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Kushwaha</surname><given-names>A. K.</given-names></name><name><surname>Nguyen</surname><given-names>S. T.</given-names></name><name><surname>Desai</surname><given-names>S. A.</given-names></name></person-group> (<year>2015</year>). <article-title>How Do Antimalarial Drugs Reach Their Intracellular Targets?</article-title>
<source>Front. Pharmacol.</source>
<volume>6</volume>. <pub-id pub-id-type="doi">10.3389/fphar.2015.00091</pub-id>
</mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Batista</surname><given-names>D. d. G. J.</given-names></name><name><surname>Batista</surname><given-names>M. M.</given-names></name><name><surname>Oliveira</surname><given-names>G. M. d.</given-names></name><name><surname>Amaral</surname><given-names>P. B. d.</given-names></name><name><surname>Lannes-Vieira</surname><given-names>J.</given-names></name><name><surname>Britto</surname><given-names>C. C.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Arylimidamide DB766, a Potential Chemotherapeutic Candidate for Chagas&#x02019; Disease Treatment</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>54</volume>, <fpage>2940</fpage>&#x02013;<lpage>2952</lpage>. <pub-id pub-id-type="doi">10.1128/aac.01617-09</pub-id>
<pub-id pub-id-type="pmid">20457822</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bennion</surname><given-names>B. J.</given-names></name><name><surname>Be</surname><given-names>N. A.</given-names></name><name><surname>McNerney</surname><given-names>M. W.</given-names></name><name><surname>Lao</surname><given-names>V.</given-names></name><name><surname>Carlson</surname><given-names>E. M.</given-names></name><name><surname>Valdez</surname><given-names>C. A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Predicting a Drug&#x02019;s Membrane Permeability: A Computational Model Validated with <italic>In Vitro</italic> Permeability Assay Data</article-title>. <source>J. Phys. Chem. B</source>
<volume>121</volume>, <fpage>5228</fpage>&#x02013;<lpage>5237</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jpcb.7b02914</pub-id>
<pub-id pub-id-type="pmid">28453293</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bern</surname><given-names>C.</given-names></name></person-group> (<year>2011</year>). <article-title>Antitrypanosomal Therapy for Chronic Chagas' Disease</article-title>. <source>N. Engl. J. Med.</source>
<volume>364</volume>, <fpage>2527</fpage>&#x02013;<lpage>2534</lpage>. <pub-id pub-id-type="doi">10.1056/nejmct1014204</pub-id>
<pub-id pub-id-type="pmid">21714649</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blaazer</surname><given-names>A. R.</given-names></name><name><surname>Orrling</surname><given-names>K. M.</given-names></name><name><surname>Shanmugham</surname><given-names>A.</given-names></name><name><surname>Jansen</surname><given-names>C.</given-names></name><name><surname>Maes</surname><given-names>L.</given-names></name><name><surname>Edink</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Fragment-Based Screening in Tandem with Phenotypic Screening Provides Novel Antiparasitic Hits</article-title>. <source>J. Biomol. Screen.</source>
<volume>20</volume>, <fpage>10</fpage>. <pub-id pub-id-type="doi">10.1177/1087057114549735</pub-id>
</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Castro</surname><given-names>J. A.</given-names></name><name><surname>deMecca</surname><given-names>M. M.</given-names></name><name><surname>Bartel</surname><given-names>L. C.</given-names></name></person-group> (<year>2006</year>). <article-title>Toxic Side Effects of Drugs Used to Treat Chagas' Disease (American Trypanosomiasis)</article-title>. <source>Hum. Exp. Toxicol.</source>
<volume>25</volume>, <fpage>471</fpage>&#x02013;<lpage>479</lpage>. <pub-id pub-id-type="doi">10.1191/0960327106het653oa</pub-id>
<pub-id pub-id-type="pmid">16937919</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Coura</surname><given-names>J. R.</given-names></name><name><surname>Borges-Pereira</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Chronic Phase of Chagas Disease: Why Should it Be Treated? A Comprehensive Review</article-title>. <source>Mem. Inst. Oswaldo Cruz</source>
<volume>106</volume>, <fpage>641</fpage>&#x02013;<lpage>645</lpage>. <pub-id pub-id-type="doi">10.1590/s0074-02762011000600001</pub-id>
<pub-id pub-id-type="pmid">22012216</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Coura</surname><given-names>J. R.</given-names></name><name><surname>Vi&#x000f1;as</surname><given-names>P. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Chagas Disease: a New Worldwide Challenge</article-title>. <source>Nature</source>
<volume>465</volume>, <fpage>S6</fpage>&#x02013;<lpage>S7</lpage>. <pub-id pub-id-type="doi">10.1038/nature09221</pub-id>
<pub-id pub-id-type="pmid">20571554</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dias</surname><given-names>J. C. P.</given-names></name></person-group> (<year>1984</year>). <article-title>Acute Chagas&#x02019; Disease</article-title>. <source>Mem. Inst. Oswaldo Cruz</source>
<volume>79</volume>, <fpage>85</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1590/s0074-02761984000500017</pub-id>
</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamers</surname><given-names>R. L.</given-names></name><name><surname>Gool</surname><given-names>T. V.</given-names></name><name><surname>Goorhuis</surname><given-names>A.</given-names></name><name><surname>Cordeiro</surname><given-names>M. A. S.</given-names></name><name><surname>Urbina</surname><given-names>J. A.</given-names></name><name><surname>Gascon</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Benznidazole for Chronic Chagas' Cardiomyopathy</article-title>. <source>N. Engl. J. Med.</source>
<volume>374</volume>, <fpage>189</fpage>&#x02013;<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc1514453</pub-id>
</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kollien</surname><given-names>A.</given-names></name><name><surname>Schaub</surname><given-names>G.</given-names></name></person-group> (<year>2000</year>). <article-title>The Development of Trypanosoma Cruzi in Triatominae</article-title>. <source>Parasitol. Today</source>
<volume>16</volume>, <fpage>381</fpage>&#x02013;<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1016/s0169-4758(00)01724-5</pub-id>
<pub-id pub-id-type="pmid">10951597</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lidani</surname><given-names>K. C. F.</given-names></name><name><surname>Andrade</surname><given-names>F. A.</given-names></name><name><surname>Bavia</surname><given-names>L.</given-names></name><name><surname>Damasceno</surname><given-names>F. S.</given-names></name><name><surname>Beltrame</surname><given-names>M. H.</given-names></name><name><surname>Messias-Reason</surname><given-names>I. J.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Chagas Disease: From Discovery to a Worldwide Health Problem</article-title>. <source>Front. Public Health</source>
<volume>7</volume>, <fpage>166</fpage>. <pub-id pub-id-type="doi">10.3389/fpubh.2019.00166</pub-id>
<pub-id pub-id-type="pmid">31312626</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martinez</surname><given-names>F.</given-names></name><name><surname>Perna</surname><given-names>E.</given-names></name><name><surname>Perrone</surname><given-names>S. V.</given-names></name><name><surname>Liprandi</surname><given-names>A. S.</given-names></name></person-group> (<year>2019</year>). <article-title>Chagas Disease and Heart Failure: An Expanding Issue Worldwide</article-title>. <source>Eur. Cardiol.</source>
<volume>14</volume>, <fpage>82</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.15420/ecr.2018.30.2</pub-id>
<pub-id pub-id-type="pmid">31360228</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meirelles</surname><given-names>M. N.</given-names></name><name><surname>de Araujo-Jorge</surname><given-names>T. C.</given-names></name><name><surname>Miranda</surname><given-names>C. F.</given-names></name><name><surname>de Souza</surname><given-names>W.</given-names></name><name><surname>Barbosa</surname><given-names>H. S.</given-names></name></person-group> (<year>1986</year>). <article-title>Interaction of <italic>Trypanosoma Cruzi</italic> with Heart Muscle Cells: Ultrastructural and Cytochemical Analysis of Endocytic Vacuole Formation and Effect upon Myogenesis <italic>In Vitro</italic>
</article-title>. <source>Eur. J. Cel Biol</source>
<volume>41</volume>, <fpage>198</fpage>&#x02013;<lpage>206</lpage>. </mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mejia</surname><given-names>A. M.</given-names></name><name><surname>Hall</surname><given-names>B. S.</given-names></name><name><surname>Taylor</surname><given-names>M. C.</given-names></name><name><surname>G&#x000f3;mez-Palacio</surname><given-names>A.</given-names></name><name><surname>Wilkinson</surname><given-names>S. R.</given-names></name><name><surname>Triana-Ch&#x000e1;vez</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Benznidazole-Resistance in Trypanosoma Cruzi Is a Readily Acquired Trait that Can Arise Independently in a Single Population</article-title>. <source>J. Infect. Dis.</source>
<volume>206</volume>, <fpage>220</fpage>&#x02013;<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jis331</pub-id>
<pub-id pub-id-type="pmid">22551809</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morillo</surname><given-names>C. A.</given-names></name><name><surname>Marin-Neto</surname><given-names>J. A.</given-names></name><name><surname>Avezum</surname><given-names>A.</given-names></name><name><surname>Sosa-Estani</surname><given-names>S.</given-names></name><name><surname>Rassi</surname><given-names>A.</given-names></name><name><surname>Rosas</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Randomized Trial of Benznidazole for Chronic Chagas&#x02019; Cardiomyopathy</article-title>. <source>N. Engl. J. Med.</source>
<volume>373</volume>, <fpage>1295</fpage>&#x02013;<lpage>1306</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa1507574</pub-id>
<pub-id pub-id-type="pmid">26323937</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pinazo</surname><given-names>M.-J.</given-names></name><name><surname>Guerrero</surname><given-names>L.</given-names></name><name><surname>Posada</surname><given-names>E.</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>E.</given-names></name><name><surname>Soy</surname><given-names>D.</given-names></name><name><surname>Gascon</surname><given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>Benznidazole-Related Adverse Drug Reactions and Their Relationship to Serum Drug Concentrations in Patients with Chronic Chagas Disease</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>57</volume>, <fpage>390</fpage>&#x02013;<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1128/aac.01401-12</pub-id>
<pub-id pub-id-type="pmid">23114763</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prata</surname><given-names>A.</given-names></name></person-group> (<year>2001</year>). <article-title>Clinical and Epidemiological Aspects of Chagas Disease</article-title>. <source>Lancet Infect. Dis.</source>
<volume>1</volume>, <fpage>92</fpage>&#x02013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(01)00065-2</pub-id>
<pub-id pub-id-type="pmid">11871482</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rassi</surname><given-names>A.</given-names><suffix>Jr</suffix></name><name><surname>Rassi</surname><given-names>A.</given-names></name><name><surname>Marin-Neto</surname><given-names>J. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Chagas Disease</article-title>. <source>The Lancet</source>
<volume>375</volume>, <fpage>1388</fpage>&#x02013;<lpage>1402</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(10)60061-x</pub-id>
</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmunis</surname><given-names>G. A.</given-names></name></person-group> (<year>1999</year>). <article-title>Prevention of Transfusional Trypanosoma Cruzi Infection in Latin America</article-title>. <source>Mem. Inst. Oswaldo Cruz</source>
<volume>94</volume>, <fpage>93</fpage>&#x02013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1590/s0074-02761999000700010</pub-id>
<pub-id pub-id-type="pmid">10677696</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sgambatti de Andrade</surname><given-names>A. L. S.</given-names></name><name><surname>Zicker</surname><given-names>F.</given-names></name><name><surname>de Oliveira</surname><given-names>R. M.</given-names></name><name><surname>Almeida e Silva</surname><given-names>S.</given-names></name><name><surname>Luquetti</surname><given-names>A.</given-names></name><name><surname>Travassos</surname><given-names>L. R.</given-names></name><etal/></person-group> (<year>1996</year>). <article-title>Randomised Trial of Efficacy of Benznidazole in Treatment of Early Trypanosoma Cruzi Infection</article-title>. <source>Lancet</source>
<volume>348</volume>, <fpage>1407</fpage>&#x02013;<lpage>1413</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(96)04128-1</pub-id>
<pub-id pub-id-type="pmid">8937280</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sijm</surname><given-names>M.</given-names></name><name><surname>Siciliano de Ara&#x000fa;jo</surname><given-names>J.</given-names></name><name><surname>Kunz</surname><given-names>S.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Edink</surname><given-names>E.</given-names></name><name><surname>Orrling</surname><given-names>K. M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Phenyldihydropyrazolones as Novel Lead Compounds against Trypanosoma Cruzi</article-title>. <source>ACS Omega</source>
<volume>4</volume>, <fpage>6585</fpage>&#x02013;<lpage>6596</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.8b02847</pub-id>
</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sijm</surname><given-names>M.</given-names></name><name><surname>Sterk</surname><given-names>G. J.</given-names></name><name><surname>Caljon</surname><given-names>G.</given-names></name><name><surname>Maes</surname><given-names>L.</given-names></name><name><surname>Esch</surname><given-names>I. J. P.</given-names></name><name><surname>Leurs</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Structure&#x02010;Activity Relationship of Phenylpyrazolones against Trypanosoma Cruzi</article-title>. <source>ChemMedChem</source>
<volume>15</volume>, <fpage>1310</fpage>&#x02013;<lpage>1321</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.202000136</pub-id>
<pub-id pub-id-type="pmid">32249532</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Torrico</surname><given-names>F.</given-names></name><name><surname>Carlier</surname><given-names>Y.</given-names></name><name><surname>Truyens</surname><given-names>C.</given-names></name><name><surname>Suarez</surname><given-names>E.</given-names></name><name><surname>Dramaix</surname><given-names>M.</given-names></name><name><surname>Alonso-vega</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Maternal Trypanosoma Cruzi Infection, Pregnancy Outcome, Morbidity, and Mortality of Congenitally Infected and Non-infected Newborns in Bolivia</article-title>. <source>Am. J. Trop. Med. Hyg.</source>
<volume>70</volume>, <fpage>201</fpage>&#x02013;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.2004.70.201</pub-id>
<pub-id pub-id-type="pmid">14993634</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="webpage">
<collab>WHO</collab> (<year>2021</year>). <article-title>Chagas Disease (American Trypanosomiasis)</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs340/en/">http://www.who.int/mediacentre/factsheets/fs340/en/</ext-link></comment> (<comment>Accessed November 05, 2018</comment>). </mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Tarleton</surname><given-names>R. L.</given-names></name></person-group> (<year>1999</year>). <article-title>Parasite Persistence Correlates with Disease Severity and Localization in Chronic Chagas&#x02019; Disease</article-title>. <source>J. Infect. Dis.</source>
<volume>180</volume>, <fpage>480</fpage>&#x02013;<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1086/314889</pub-id>
<pub-id pub-id-type="pmid">10395865</pub-id></mixed-citation></ref></ref-list><sec id="s8"><title>Glossary</title><def-list><def-item><term id="G1-fchem.2021.608438">ACN</term><def><p>acetonitrile</p></def></def-item><def-item><term id="G2-fchem.2021.608438">AcOH</term><def><p>acetic acid</p></def></def-item><def-item><term id="G3-fchem.2021.608438">BINAP</term><def><p>2,2&#x02032;-bis(diphenylphosphino)-1.,1&#x02032;-binaphthyl</p></def></def-item><def-item><term id="G4-fchem.2021.608438">bs</term><def><p>broad singlet</p></def></def-item><def-item><term id="G5-fchem.2021.608438">d</term><def><p>days</p></def></def-item><def-item><term id="G6-fchem.2021.608438">d</term><def><p>doublet</p></def></def-item><def-item><term id="G7-fchem.2021.608438">DBN</term><def><p>1,5-Diazabicyclo[4.3.0]non-5-ene</p></def></def-item><def-item><term id="G8-fchem.2021.608438">DCE</term><def><p>dichlorethane</p></def></def-item><def-item><term id="G9-fchem.2021.608438">DCM</term><def><p>dichloromethane</p></def></def-item><def-item><term id="G10-fchem.2021.608438">dd</term><def><p>double doublet</p></def></def-item><def-item><term id="G11-fchem.2021.608438">DIPEA</term><def><p>
<italic>N</italic>,<italic>N</italic>-diisopropylethylamine</p></def></def-item><def-item><term id="G12-fchem.2021.608438">DMAP</term><def><p>4-dimethylaminopyridine</p></def></def-item><def-item><term id="G13-fchem.2021.608438">DME</term><def><p>dimethoxyethane</p></def></def-item><def-item><term id="G14-fchem.2021.608438">DMF</term><def><p>dimethylformamide</p></def></def-item><def-item><term id="G15-fchem.2021.608438">DMSO</term><def><p>dimethylsulfoxide</p></def></def-item><def-item><term id="G16-fchem.2021.608438">dt</term><def><p>double triplet</p></def></def-item><def-item><term id="G17-fchem.2021.608438">DTU</term><def><p>discrete typing unit</p></def></def-item><def-item><term id="G18-fchem.2021.608438">EDCI</term><def><p>1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide</p></def></def-item><def-item><term id="G19-fchem.2021.608438">ESI</term><def><p>electron spray ionization</p></def></def-item><def-item><term id="G20-fchem.2021.608438">EtOAc</term><def><p>ethylacetate</p></def></def-item><def-item><term id="G21-fchem.2021.608438">EtOH</term><def><p>ethanol</p></def></def-item><def-item><term id="G22-fchem.2021.608438">FCS</term><def><p>fetal calf serum</p></def></def-item><def-item><term id="G23-fchem.2021.608438">h</term><def><p>heptet</p></def><def><p>hour</p></def></def-item><def-item><term id="G24-fchem.2021.608438">h</term><def><p>heptet</p></def><def><p>hour</p></def></def-item><def-item><term id="G25-fchem.2021.608438">HOBt</term><def><p>hydroxybenzotriazole</p></def></def-item><def-item><term id="G26-fchem.2021.608438">HPLC</term><def><p>high pressure liquid chromatography</p></def></def-item><def-item><term id="G27-fchem.2021.608438">HRMS</term><def><p>high resolution mass spectroscopy</p></def></def-item><def-item><term id="G28-fchem.2021.608438">Hz</term><def><p>Hertz</p></def></def-item><def-item><term id="G29-fchem.2021.608438">i-PrOH</term><def><p>isopropanol</p></def></def-item><def-item><term id="G30-fchem.2021.608438">LC-MS</term><def><p>liquid chromatography mass spectroscopy</p></def></def-item><def-item><term id="G31-fchem.2021.608438">m</term><def><p>minute</p></def></def-item><def-item><term id="G32-fchem.2021.608438">m</term><def><p>multiplet</p></def></def-item><def-item><term id="G33-fchem.2021.608438">MeOH</term><def><p>methanol</p></def></def-item><def-item><term id="G34-fchem.2021.608438">MRC-5</term><def><p>medical research council strain 5</p></def></def-item><def-item><term id="G35-fchem.2021.608438">MTBE</term><def><p>methyl tertbutyl ether</p></def></def-item><def-item><term id="G36-fchem.2021.608438">NaOtBu</term><def><p>sodium tert-butoxide</p></def></def-item><def-item><term id="G37-fchem.2021.608438">o.n.</term><def><p>overnight</p></def></def-item><def-item><term id="G38-fchem.2021.608438">p</term><def><p>pentet</p></def></def-item><def-item><term id="G39-fchem.2021.608438">PDE4NPD</term><def><p>phosphodiesterase inhibitors for neglected parasitic disease</p></def></def-item><def-item><term id="G40-fchem.2021.608438">pIC<sub>50</sub></term><def><p>-log of the value at which 50% of growth is inhibited</p></def></def-item><def-item><term id="G41-fchem.2021.608438">rt</term><def><p>room temperature</p></def></def-item><def-item><term id="G42-fchem.2021.608438">s</term><def><p>singlet</p></def></def-item><def-item><term id="G43-fchem.2021.608438">SAR</term><def><p>structure activity relationship</p></def></def-item><def-item><term id="G44-fchem.2021.608438">t</term><def><p>triplet</p></def></def-item><def-item><term id="G45-fchem.2021.608438">T3P</term><def><p>propylphosphonic anhydride</p></def></def-item><def-item><term id="G46-fchem.2021.608438">Tcr</term><def><p>
<italic>Trypanosoma cruzi</italic>
</p></def></def-item><def-item><term id="G47-fchem.2021.608438">TEA</term><def><p>triethylamine</p></def></def-item><def-item><term id="G48-fchem.2021.608438">q</term><def><p>quartet</p></def></def-item><def-item><term id="G49-fchem.2021.608438">THF</term><def><p>tetrahydrofuran</p></def></def-item><def-item><term id="G50-fchem.2021.608438">TLC</term><def><p>thin layer chromatography</p></def></def-item><def-item><term id="G51-fchem.2021.608438">UV</term><def><p>ultraviolet</p></def></def-item></def-list></sec></back></article>